Isolated Sulfite Oxidase Deficiency

Mendelian MONDO:0010089 Pathograph 21 Show in embeddings browser Metabolic Disease Inborn Error of Metabolism

Isolated sulfite oxidase deficiency (ISOD) is an ultra-rare, autosomal recessive inborn error of sulfur (cysteine) catabolism caused by biallelic loss-of-function variants in SUOX. SUOX encodes sulfite oxidase, the molybdenum-cofactor- and heme-dependent enzyme of the mitochondrial intermembrane space that catalyses the terminal step of sulfur amino acid degradation, oxidising sulfite to sulfate. When the enzyme is lost, sulfite accumulates and is shunted into two diagnostic metabolites: S-sulfocysteine, formed by reaction of sulfite with cystine, and thiosulfate. S-sulfocysteine is a structural analog of glutamate and behaves as an NMDA-receptor agonist, so the accumulating metabolite is not merely a marker but the proximate neurotoxin — it drives calcium influx, calpain activation and calpain-dependent degradation of the inhibitory postsynaptic scaffold gephyrin, simultaneously raising excitatory drive and stripping GABAergic inhibition. The resulting excitotoxic injury produces the characteristic clinical picture: classic ISOD presents in the first hours to days of life with pharmacoresistant seizures, feeding difficulty and rapidly progressive encephalopathy with opisthotonus and spastic quadriplegia, followed by progressive microcephaly, profound intellectual disability, cerebral atrophy with cystic encephalomalacia, and death in infancy. A milder late-onset form manifests between six and 18 months with ectopia lentis, a dystonic-choreoathetotic movement disorder and developmental regression, and is associated with biallelic missense genotypes that retain residual activity. Lens subluxation or dislocation is a hallmark at any severity. Because the same metabolic block occurs downstream of molybdenum cofactor deficiency (MoCD), which additionally impairs xanthine dehydrogenase, distinguishing ISOD from MoCD by uric acid and urinary oxypurines is diagnostically essential — MoCD type A is treatable whereas no disease-modifying therapy exists for ISOD.

Ask OpenScientist

Ask a research question about Isolated Sulfite Oxidase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
13
Pathophys.
19
Phenotypes
1
Hypotheses
2
Gaps
21
Pathograph
1
Genes
9
Medical Actions
2
Subtypes
1
Differentials
10
References
🏷

Classifications

ICIMD (Inherited Metabolic Disorders)
sulfur containing amino acids
🔗

Mappings

MONDO
MONDO:0010089 isolated sulfite oxidase deficiency
skos:exactMatch OMIM:272300
MONDO:0010089 (isolated sulfite oxidase deficiency) cross-references OMIM:272300 and Orphanet:99731 and declares SUOX (HGNC:11460) as its causal gene, matching the gene and OMIM identifier of the curated entity.
👪

Inheritance

1
Autosomal recessive HP:0000007
ISOD is caused by biallelic pathogenic SUOX variants. Heterozygous parents are asymptomatic obligate carriers; each sibling of a proband has a 25% recurrence risk.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"ISOD is inherited in an autosomal recessive manner."
GeneReviews states the autosomal recessive mode of inheritance.
PMID:28933809 SUPPORT Human Clinical
"The diagnosis is confirmed by identification of biallelic pathogenic variants in SUOX by molecular genetic testing."
Confirms that biallelic SUOX variants define the molecular diagnosis.
◆

Subtypes

2
Classic early-onset (severe) ISOD
SUOX hgnc:11460 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in SUOX (hgnc:11460). hgnc:11460 is a gene from the HUGO Gene Nomenclature Committee.
Neonatal-onset severe form presenting in the first hours to days of life with intractable seizures, feeding difficulties and rapidly progressive encephalopathy with opisthotonus and spastic quadriplegia, followed by progressive microcephaly, profound intellectual disability and death in infancy.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and..."
Defines the classic early-onset severe subtype.
Late-onset (mild) ISOD
SUOX hgnc:11460 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in SUOX (hgnc:11460). hgnc:11460 is a gene from the HUGO Gene Nomenclature Committee.
Milder form manifesting between six and 18 months of age with variably present ectopia lentis, developmental delay or regression, a movement disorder of dystonia and choreoathetosis, ataxia and rarely metabolic stroke. The course may be progressive or episodic. Biallelic missense genotypes are enriched in this presentation.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
Defines the late-onset milder subtype and its distinguishing movement-disorder phenotype.
PMID:36303223 SUPPORT Human Clinical
"suggest that missense mutations are associated with mild and atypical symptoms"
Links the milder/atypical presentations to biallelic missense genotypes.
◈

Mechanistic Hypotheses

1
Sulfite-Mediated Zonular Disulfide Reduction
zonular_disulfide_reduction EMERGING
The widely repeated explanation for ectopia lentis in ISOD is that sulfite, a nucleophilic anion, reduces the disulfide bonds cross-linking the fibrillin-rich zonular fibres that suspend the lens, weakening them until the lens subluxes. It is chemically plausible and would explain the phenotypic convergence with homocystinuria and Marfan syndrome, where zonular integrity also fails. However, no primary study demonstrating the step in ISOD (or SUOX-deficient) zonular tissue was identified during curation, so the causal edge from Sulfite Accumulation to Ectopia Lentis is typed INDIRECT_UNKNOWN_INTERMEDIATES and opted into this group rather than presented as established. See the `ectopia_lentis_mechanism_unresolved` discussion for the experiments that would resolve it.
Status EMERGING rather than CANONICAL deliberately: the clinical association is solid, the mechanism is not.
Pathograph links
Sulfite Accumulation -> Ectopia Lentis INDIRECT UNKNOWN INTERMEDIATES Accumulating sulfite is presumed to reach the ocular zonule and compromise the disulfide-rich fibrillin microfibrils that suspend the lens. The intermediates are unknown and no primary study establishes the step in ISOD tissue, so the edge is typed INDIRECT_UNKNOWN_INTERMEDIATES and assigned to the `zonular_disulfide_reduction` hypothesis group rather than asserted as an evidenced mechanism. Its evidence is the clinical co-occurrence only.
?

Discussions and Knowledge Gaps

2
Does S-sulfocysteine drive NMDA-receptor-dependent excitotoxicity in human isolated sulfite oxidase deficiency to the same degree demonstrated in molybdenum cofactor deficiency models?
HUMAN MODEL MISMATCH OPEN ssc_nmda_evidence_from_mocd
Attached to
pathophysiology#NMDA Receptor Overactivation and Calcium Influx pathophysiology#Calpain Activation and Gephyrin Degradation pathophysiology#Loss of GABAergic Inhibition
The mechanistic chain curated here — SSC acting as an NMDA-receptor agonist, calcium influx, calpain activation, calpain-dependent gephyrin degradation and loss of GABAergic synapses — was demonstrated in primary murine neurons and in a tungstate-induced molybdenum cofactor deficiency mouse, not in ISOD patients or ISOD-derived human neurons. The transfer is biologically reasonable because MoCD causes a secondary sulfite oxidase block and therefore the same accumulating metabolite, and because a full SUOX-knockout mouse now exists. But the two disorders are not metabolically identical: MoCD additionally loses xanthine dehydrogenase and aldehyde oxidase, so MoCD models carry purine and aldehyde perturbations that ISOD does not. A dissenting in-vitro report in HT-22 hippocampal cells further found that glutamate-receptor blockade did NOT reverse SSC cytotoxicity, implying at least one receptor-independent death pathway. Whether NMDA-receptor antagonism would be neuroprotective in human ISOD is therefore genuinely open, and it matters directly because it is the only mechanism-based therapeutic hypothesis currently on the table for a disorder with no disease-modifying treatment.
Proposed experiments
NMDA-receptor antagonism in the SUOX-knockout mouse
isod_nmda_antagonism_suox_ko
Test whether memantine or another NMDA-receptor antagonist is neuroprotective in the SUOX-knockout mouse, in which the metabolic lesion is isolated, rather than in the tungstate-induced MoCD model where xanthine dehydrogenase and aldehyde oxidase are also inhibited.
Decision criterion
Significant improvement in survival and in seizure/neurobehavioural endpoints versus vehicle would support translating the MoCD mechanism to ISOD; absence of benefit would indicate the excitotoxic arm is not rate-limiting in isolated SUOX loss.
ISOD patient iPSC-derived neuron challenge
isod_ipsc_neuron_ssc_challenge
Differentiate neurons from ISOD-patient iPSCs and isogenic corrected controls and measure SSC-driven calcium influx, calpain activation and gephyrin loss.
Decision criterion
Reproduction of the calcium/calpain/gephyrin cascade in human ISOD neurons would close the species and disease-context gap in the current evidence.
Reconciliation of the HT-22 negative result
isod_ht22_discrepancy_resolution
Compare SSC cytotoxicity with and without glutamate-receptor blockade across primary neurons, HT-22 cells and human iPSC-derived neurons under matched SSC concentrations and exposure times.
Decision criterion
Consistent receptor-independent toxicity across models would establish a second, parallel death pathway (oxytosis/necrosis) that the current pathograph does not represent.
Show evidence (2 references)
PMID:29106383 SUPPORT Model Organism
"the NMDA-R antagonist memantine was protective against the manifestation of symptoms in a tungstate-induced MoCD mouse model"
The therapeutic proof-of-concept was obtained in a tungstate-induced MoCD mouse, not in an ISOD model, which is the source of the translational uncertainty.
PMID:39749013 REFUTE In Vitro
"The cytotoxic effects of SSC were not reversed by glutamate receptor blocker administration."
A direct in-vitro challenge to the receptor-dependent model: in HT-22 hippocampal cells, glutamate-receptor blockade did not rescue SSC toxicity, indicating at least one receptor-independent death pathway.
By what mechanism does sulfite accumulation dislocate the ocular lens in ISOD?
KNOWLEDGE GAP OPEN ectopia_lentis_mechanism_unresolved
Attached to
pathophysiology#Ectopia Lentis
Ectopia lentis is the one consistent extraneurological feature of ISOD and can be the presenting sign of the late-onset form, yet the pathograph has no evidenced step connecting sulfite accumulation to zonular failure. The widely repeated explanation — that sulfite, a nucleophile, cleaves the disulfide bonds that cross-link the fibrillin-rich zonular fibres suspending the lens — is mechanically plausible and would explain the phenotypic overlap with homocystinuria and Marfan syndrome, but no primary study establishing it in ISOD tissue was identified during curation. The node is therefore curated as a consequence carrying a clinical association only, and the proposed zonular mechanism is deliberately excluded from the evidenced causal chain.
Proposed experiments
Zonular fibre analysis in SUOX-deficient tissue
isod_zonule_fibrillin_analysis
Histological and biochemical analysis of zonular fibres from SUOX-knockout mice or from ISOD autopsy/lensectomy material, assaying fibrillin-1 disulfide integrity against age-matched controls.
Decision criterion
Demonstration of reduced disulfide cross-linking or fragmented fibrillin microfibrils in SUOX-deficient zonules would convert the hypothesis into an evidenced pathograph step.
In-vitro sulfite challenge of fibrillin microfibrils
isod_sulfite_microfibril_challenge
Expose purified fibrillin microfibrils to pathophysiological sulfite concentrations and measure disulfide reduction and mechanical failure.
Decision criterion
Concentration-dependent disulfide reduction and loss of tensile integrity at patient-range sulfite levels would establish chemical plausibility.
Genotype-stratified age at lens dislocation
isod_genotype_lens_onset_correlation
Correlate age at lens subluxation with residual SUOX activity (or genotype class) across the published patient spectrum.
Decision criterion
A dose-dependent relationship between residual enzyme activity and later dislocation would support a cumulative sulfite-exposure mechanism.
⚙

Pathophysiology

13
SUOX Sulfite Oxidase Deficiency
Biallelic loss-of-function variants in SUOX abolish the activity of sulfite oxidase, the molybdenum-cofactor- and heme-containing homodimeric enzyme of the mitochondrial intermembrane space that catalyses the terminal, irreversible step of sulfur amino acid catabolism — oxidation of sulfite to sulfate. Because the lesion is confined to SUOX itself, the other molybdenum-cofactor-dependent enzymes (notably xanthine dehydrogenase) remain intact, which is the biochemical basis for distinguishing ISOD from molybdenum cofactor deficiency.
SUOX hgnc:11460 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SUOX (hgnc:11460). hgnc:11460 is a gene from the HUGO Gene Nomenclature Committee.
sulfur amino acid catabolic process GO:0000098 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased sulfur amino acid catabolic process (GO:0000098). GO:0000098 is a biological process from the Gene Ontology. ↓ DECREASED L-cysteine catabolic process GO:0019448 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased L-cysteine catabolic process (GO:0019448). GO:0019448 is a biological process from the Gene Ontology. ↓ DECREASED
sulfite oxidase activity GO:0008482 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased sulfite oxidase activity (GO:0008482). GO:0008482 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Sulfite Accumulation Loss of the terminal oxidative step leaves sulfite, generated continuously from dietary and endogenous cysteine catabolism, without a route to sulfate, so it accumulates to toxic concentrations.
Show evidence (3 references)
PMID:33335014 SUPPORT Human Clinical
"Isolated sulfite oxidase deficiency is a rare autosomal recessive inborn error of sulfur metabolism."
Establishes ISOD as a recessive inborn error of sulfur metabolism.
PMID:9050047 SUPPORT Human Clinical
"Liver sulfite oxidase activity was not detectable but xanthine dehydrogenase activity was normal."
Demonstrates the defining enzymatic signature of the isolated form — absent sulfite oxidase activity with preserved xanthine dehydrogenase, i.e. an intact molybdenum cofactor.
PMID:41178722 SUPPORT Model Organism
"Sulfite oxidase (SOX) deficiency is a rare inborn error of cysteine metabolism resulting in severe neurological damage."
Places the enzymatic lesion within cysteine catabolism and links it to the neurological outcome. Tagged MODEL_ORGANISM because this is the framing sentence of a full-body SOX-knockout mouse study rather than a human observation; the human evidence for the same claim is the preceding two items.
Sulfite Accumulation
Sulfite, a reactive nucleophilic anion, accumulates in tissues and body fluids. It is disposed of by two secondary routes that generate the diagnostic metabolites of ISOD: reaction with cystine to form S-sulfocysteine, and conversion to thiosulfate. The diversion of cystine into S-sulfocysteine also contributes to the paradoxical fall in plasma cystine, and organic sulfate output falls because the oxidative route to sulfate is blocked.
Sulfite-Mediated Zonular Disulfide Reduction
Downstream
S-Sulfocysteine Accumulation Sulfite reacts with cystine to generate S-sulfocysteine, which is elevated in plasma and urine of every reported patient.
Ectopia Lentis Accumulating sulfite is presumed to reach the ocular zonule and compromise the disulfide-rich fibrillin microfibrils that suspend the lens. The intermediates are unknown and no primary study establishes the step in ISOD tissue, so the edge is typed INDIRECT_UNKNOWN_INTERMEDIATES and assigned to the `zonular_disulfide_reduction` hypothesis group rather than asserted as an evidenced mechanism. Its evidence is the clinical co-occurrence only. Sulfite-Mediated Zonular Disulfide Reduction
Loss of Protein S-Persulfidation and Hydrogen Sulfide Release Accumulating sulfite reacts with protein persulfides, releasing hydrogen sulfide and stripping the persulfide post-translational modification from a large fraction of the proteome.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
Documents the full biochemical consequence of the block — sulfite, thiosulfate and S-sulfocysteine accumulation with low organic sulfate and low total homocysteine.
S-Sulfocysteine Accumulation
S-sulfocysteine (SSC) is a structural analog of glutamate. Its accumulation converts the metabolic block into a neurochemical lesion, because SSC is not an inert marker but an agonist at ionotropic glutamate receptors.
Downstream
NMDA Receptor Overactivation and Calcium Influx SSC acts as an NMDA-receptor agonist, producing calcium influx and downstream excitotoxic signalling.
Show evidence (2 references)
PMID:16140720 SUPPORT Human Clinical
"Plasma or urinary S-sulfocysteine levels were elevated in all cases."
Human evidence that S-sulfocysteine accumulates in every reported ISOD patient, establishing the metabolite elevation itself.
PMID:31001109 SUPPORT Model Organism
"In humans, SOX deficiency causes the formation of the glutamate analog S-Sulfocysteine (SSC) resulting in a constant overstimulation of ionotropic glutamatergic receptors."
Frames the accumulating SSC as a glutamate analog that overstimulates ionotropic glutamate receptors. Tagged MODEL_ORGANISM because the sentence is introductory framing in a zebrafish study, not human data; the human metabolite evidence is the preceding item.
NMDA Receptor Overactivation and Calcium Influx
SSC, a structural analog of glutamate, acts as an agonist at the NMDA receptor. The resulting receptor overactivation opens the associated cation conductance and loads the neuron with calcium — the proximal molecular event of the excitotoxic arm. Receptor activation and the calcium entry it gates are curated as one node because they are a single pharmacologically inseparable step: blocking either the receptor or the calcium influx abolishes the toxicity equally.
calcium ion import GO:0070509 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased calcium ion import (GO:0070509). GO:0070509 is a biological process from the Gene Ontology. ↑ INCREASED
NMDA glutamate receptor activity GO:0004972 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased NMDA glutamate receptor activity (GO:0004972). GO:0004972 is a molecular function from the Gene Ontology. ↑ INCREASED
Downstream
Calpain Activation and Gephyrin Degradation Calcium loading activates the calcium-dependent protease calpain, which proteolyses the inhibitory postsynaptic scaffold gephyrin.
Excitotoxic Neuronal Death and Cystic Encephalomalacia Sustained excitotoxic calcium loading kills neurons; in the neonatal brain the resulting injury is severe enough to cavitate, producing cortical necrosis and cystic white matter change.
Show evidence (1 reference)
PMID:29106383 SUPPORT In Vitro
"demonstrated that it acts as an N-methyl D-aspartate receptor (NMDA-R) agonist, leading to calcium influx and downstream cell signaling events and neurotoxicity"
Establishes SSC agonism at the NMDA receptor and the calcium influx it gates.
Calpain Activation and Gephyrin Degradation
Calcium-activated calpain degrades gephyrin, the scaffold protein that clusters and anchors glycine and GABA-A receptors at inhibitory postsynapses. This is the step that converts a glutamatergic insult into an inhibitory-synapse lesion, and is why the excitation/inhibition shift in ISOD is two-directional rather than purely excitatory.
protein catabolic process GO:0030163 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased protein catabolic process (GO:0030163). GO:0030163 is a biological process from the Gene Ontology. ↑ INCREASED
calcium-dependent cysteine-type endopeptidase activity GO:0004198 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased calcium-dependent cysteine-type endopeptidase activity (GO:0004198). GO:0004198 is a molecular function from the Gene Ontology. ↑ INCREASED
Downstream
Loss of GABAergic Inhibition Loss of the gephyrin scaffold disperses GABA-A receptor clusters and destroys inhibitory synapses, reducing GABAergic signalling.
Show evidence (1 reference)
PMID:29106383 SUPPORT In Vitro
"SSC treatment activated the protease calpain, and calpain-dependent degradation of the inhibitory synaptic protein gephyrin subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic synapses."
Demonstrates calpain activation by SSC and calpain-dependent proteolysis of gephyrin.
Loss of GABAergic Inhibition
Destruction of inhibitory synapses lowers GABAergic tone. Combined with the raised glutamatergic drive upstream, ISOD shifts the excitation/inhibition balance from both directions at once — increased excitation plus actively destroyed inhibition — which is a mechanistic explanation for the pharmacoresistance of the neonatal seizures, since most anti-seizure medications act by potentiating the very GABAergic synapses that are being lost.
GABAergic Neuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic Neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology.
GABA Signaling Pathway GO:0007214 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased GABA Signaling Pathway, annotated with gamma-aminobutyric acid signaling pathway (GO:0007214). GO:0007214 is a biological process from the Gene Ontology. ↓ DECREASED GABA-A receptor clustering GO:0097112 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased GABA-A receptor clustering, annotated with gamma-aminobutyric acid receptor clustering (GO:0097112). GO:0097112 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Neonatal Epileptic Encephalopathy The excitation/inhibition imbalance manifests clinically as intractable neonatal seizures with rapidly progressive encephalopathy.
Show evidence (1 reference)
PMID:29106383 SUPPORT In Vitro
"SSC treatment activated the protease calpain, and calpain-dependent degradation of the inhibitory synaptic protein gephyrin subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic synapses."
Establishes loss of GABAergic synapses as the endpoint of the calpain-gephyrin arm and shows that it feeds back to exacerbate the excitotoxicity.
Loss of Protein S-Persulfidation and Hydrogen Sulfide Release
A second, more recently defined arm of the pathophysiology: accumulating sulfite strips persulfide groups from cysteine residues across the proteome, releasing hydrogen sulfide and abolishing a redox-relevant post-translational modification on enzymes of amino acid and fatty acid metabolism and of cytosolic iron-sulfur cluster biogenesis. This connects ISOD to the wider hydrogen sulfide disorders (compare ETHE1 deficiency) and provides a mechanistic rationale for sulfite scavenging as therapy.
Downstream
Mitochondrial Dysfunction and Metabolic Rewiring Loss of persulfidation across metabolic enzymes is accompanied by an altered urinary amino acid profile indicating metabolic rewiring and mitochondrial dysfunction.
Show evidence (1 reference)
PMID:41178722 SUPPORT Model Organism
"Mass spectrometry analysis of total protein persulfidome identified a major loss of S-persulfidation in 20% of the proteome, affecting enzymes in amino acids, fatty acid metabolism, and cytosolic iron-sulfur cluster biogenesis."
Quantifies the proteome-wide loss of persulfidation in the SOX-knockout mouse.
Mitochondrial Dysfunction and Metabolic Rewiring
Secondary bioenergetic failure. Human neuropathology in ISOD — cortical necrosis with extensive cavitating leukoencephalopathy resembling perinatal asphyxia — has long been read as evidence that an energy-deficiency component contributes alongside excitotoxicity.
Downstream
Excitotoxic Neuronal Death and Cystic Encephalomalacia Bioenergetic compromise lowers the threshold for excitotoxic injury and contributes to the cavitating pattern of destruction.
Show evidence (1 reference)
PMID:9050047 SUPPORT Human Clinical
"Neuropathological findings of cortical necrosis and extensive cavitating leukoencephalopathy were reminiscent of those seen in severe perinatal asphyxia suggesting an etiology of energy deficiency."
Human autopsy findings interpreted by the authors as indicating an energy-deficiency contribution to the brain injury.
Excitotoxic Neuronal Death and Cystic Encephalomalacia
Neuronal death in the immature brain produces the imaging and neuropathological signature of ISOD — diffuse cerebral (and cerebellar) atrophy, cystic white matter change and ventriculomegaly — found in every patient imaged in the largest published review.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
neuron apoptotic process GO:0051402 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neuron apoptotic process (GO:0051402). GO:0051402 is a biological process from the Gene Ontology. ↑ INCREASED
cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology. white matter UBERON:0002316 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in white matter (UBERON:0002316). UBERON:0002316 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Progressive Microcephaly and Profound Neurodevelopmental Impairment Ongoing destruction of brain parenchyma from birth produces acquired, progressive microcephaly and profound intellectual disability.
Show evidence (2 references)
PMID:16140720 SUPPORT Human Clinical
"Cerebral atrophy and cystic encephalomalacia were observed with neuroradiologic imaging and were noted in all 3 postmortem reports of isolated sulfite oxidase deficiency."
Documents cerebral atrophy and cystic encephalomalacia on imaging and at autopsy.
PMID:28980090 SUPPORT Human Clinical
"In all patients in whom brain magnetic resonance imaging/computed tomography (MRI/CT) was performed, brain abnormalities were found."
Establishes that structural brain injury is an invariant finding in imaged patients.
Neonatal Epileptic Encephalopathy
The clinical presentation of the excitation/inhibition lesion: pharmacoresistant seizures beginning within the first 72 hours of life in most patients, with axial hypotonia, peripheral hypertonia, opisthotonus and feeding difficulty.
brain UBERON:0000955 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brain (UBERON:0000955). UBERON:0000955 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Death in Infancy In the classic form the encephalopathy is rapidly fatal.
Show evidence (2 references)
PMID:28980090 SUPPORT Human Clinical
"Onset occurred mostly during the first 72 h of life (57%) and within the first year of life in all but two patients (96%)."
Establishes the neonatal/early-infantile onset of the encephalopathy.
PMID:28980090 SUPPORT Human Clinical
"All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
Quantifies the neurological presentation, including pharmacoresistant seizures in 84% of patients.
Progressive Microcephaly and Profound Neurodevelopmental Impairment
Acquired progressive microcephaly with profound intellectual disability and spastic quadriplegia, the end state of the destructive encephalopathy in survivors of the neonatal period.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
Documents developmental delay in 97% of reported patients.
Death in Infancy
Classic ISOD is usually fatal within the first months of life; the milder late-onset form is compatible with longer survival.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Children usually die during the first few months of life."
Documents the usual fatal outcome of classic ISOD in infancy.
Ectopia Lentis
Subluxation or frank dislocation of the ocular lens is the characteristic extraneurological feature of ISOD and may be the presenting sign in the milder late-onset form, sometimes with otherwise minimal neurological involvement. It typically becomes evident after the newborn period. The mechanism is presumed to involve sulfite-mediated damage to the disulfide-rich zonular fibres that suspend the lens, but this remains a hypothesis rather than a demonstrated step (see discussions).
lens of camera-type eye UBERON:0000965 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in lens of camera-type eye (UBERON:0000965). UBERON:0000965 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"Lens subluxation or dislocation, another characteristic finding, may be evident after the newborn period."
Documents lens subluxation/dislocation as a characteristic finding appearing after the newborn period.
PMID:36303223 SUPPORT Human Clinical
"Isolated sulfite oxidase deficiency (ISOD) caused by sulfite oxidase gene (SUOX) mutations is a rare neurometabolic disease associated with ectopia lentis (EL)."
Confirms the ISOD-ectopia lentis association in a cohort ascertained through congenital ectopia lentis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Isolated Sulfite Oxidase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

19
Digestive 1
Feeding difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and..."
Lists feeding difficulties among the presenting features of classic ISOD.
Eye 1
Ectopia lentis HP:0001083 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ectopia lentis (HP:0001083). HP:0001083 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"Lens subluxation or dislocation, another characteristic finding, may be evident after the newborn period."
Documents ectopia lentis as a characteristic finding.
PMID:33335014 SUPPORT Human Clinical
"Clinical features generally include devastating neurologic dysfunction, ectopia lentis, and increased urinary excretion of sulfite, thiosulfate, and S-sulfocysteine."
Lists ectopia lentis among the general clinical features of ISOD.
Musculoskeletal 2
Hypertonia HP:0001276 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertonia (HP:0001276). HP:0001276 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
Peripheral hypertonia is reported as part of the invariant neurological presentation.
Opisthotonus HP:0002179 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Opisthotonus (HP:0002179). HP:0002179 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and..."
Lists opisthotonus among the characteristic tone abnormalities of classic ISOD.
Nervous System 10
Global developmental delay VERY_FREQUENT HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
Reports developmental delay in 97% of reviewed patients, supporting the VERY_FREQUENT (80-99%) frequency band.
Dystonia HP:0001332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dystonia (HP:0001332). HP:0001332 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
Documents dystonia as part of the late-onset movement disorder.
Choreoathetosis HP:0001266 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Choreoathetosis (HP:0001266). HP:0001266 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
Documents choreoathetosis in the late-onset form.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
Documents ataxia in the late-onset form.
Developmental regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Developmental regression (HP:0002376). HP:0002376 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
Documents developmental delay/regression in the late-onset form.
Hemiparesis VERY_RARE HP:0001269 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hemiparesis (HP:0001269). HP:0001269 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
Describes acute hemiplegia as a rare ("(rarely)") manifestation, supporting the VERY_RARE frequency band.
Cerebral atrophy HP:0002059 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral atrophy (HP:0002059). HP:0002059 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16140720 SUPPORT Human Clinical
"Cerebral atrophy and cystic encephalomalacia were observed with neuroradiologic imaging and were noted in all 3 postmortem reports of isolated sulfite oxidase deficiency."
Documents cerebral atrophy on imaging and at postmortem.
Cerebellar atrophy HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar atrophy (HP:0001272). HP:0001272 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"radiological findings (including cerebral/cerebellar atrophy, cystic white matter changes, ventriculomegaly)"
Lists cerebellar atrophy among the radiological findings reviewed.
Leukoencephalopathy HP:0002352 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Leukoencephalopathy (HP:0002352). HP:0002352 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:9050047 SUPPORT Human Clinical
"Neuropathological findings of cortical necrosis and extensive cavitating leukoencephalopathy were reminiscent of those seen in severe perinatal asphyxia suggesting an etiology of energy deficiency."
Documents extensive cavitating leukoencephalopathy at autopsy.
PMID:28980090 SUPPORT Human Clinical
"radiological findings (including cerebral/cerebellar atrophy, cystic white matter changes, ventriculomegaly)"
Lists cystic white matter changes among the radiological findings reviewed.
Ventriculomegaly HP:0002119 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ventriculomegaly (HP:0002119). HP:0002119 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"radiological findings (including cerebral/cerebellar atrophy, cystic white matter changes, ventriculomegaly)"
Lists ventriculomegaly among the radiological findings reviewed.
Other 5
Neonatal seizure HP:0032807 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal seizure (HP:0032807). HP:0032807 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28980090 SUPPORT Human Clinical
"All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
Reports (pharmacoresistant) seizures in 84% of 47 reviewed patients. No `frequency` band is asserted here: the 84% figure counts seizures at any age, whereas this phenotype is the neonatal-onset term (HP:0032807), for which the source reports 57% (first 72 h). Per docs/frequency-evidence-guidelines.md the band is omitted rather than derived from a non-matching denominator.
PMID:28980090 SUPPORT Human Clinical
"Onset occurred mostly during the first 72 h of life (57%) and within the first year of life in all but two patients (96%)."
Establishes the neonatal timing of onset.
Axial hypotonia HP:0008936 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Axial hypotonia (HP:0008936). HP:0008936 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
Documents neonatal axial hypotonia as part of the invariant neurological presentation. No `frequency` band is asserted: the reported 100% covers the disjunction "axial hypotonia and/or peripheral hypertonia", so it does not quantify axial hypotonia on its own, and per docs/frequency-evidence-guidelines.md the band is omitted rather than inferred from a compound denominator.
Spastic tetraplegia HP:0002510 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spastic tetraplegia (HP:0002510). HP:0002510 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and..."
Documents spastic quadriplegia and pyramidal signs in classic ISOD.
Progressive microcephaly HP:0000253 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive microcephaly (HP:0000253), qualified as course progressive. HP:0000253 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and..."
Documents progressive microcephaly following the neonatal encephalopathy.
Profound intellectual disability HP:0002187 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Profound intellectual disability (HP:0002187). HP:0002187 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and..."
Documents profound intellectual disability as an outcome of classic ISOD.
🧬

Genetic Associations

1
SUOX deficiency
Gene: SUOX hgnc:11460 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SUOX (hgnc:11460). hgnc:11460 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (5 references)
PMID:33335014 SUPPORT Human Clinical
"Both patients have a homozygous 4-bp deletion, 1347-1350delTTGT in the sulfite oxidase gene (SUOX), predicting a premature termination of the sulfite oxidase protein leading to absence of the carboxy-terminal third portion of the protein."
Describes the Manitoba founder truncating allele and its predicted protein consequence.
PMID:33335014 SUPPORT Human Clinical
"This domain contains most of the contact sites essential for enzyme dimerization."
Explains why loss of the carboxy-terminal third abolishes enzyme function.
PMID:9050047 SUPPORT Human Clinical
"A point mutation that resulted in a truncated protein missing the molybdenum-binding site has been identified."
Documents an early truncating allele removing the molybdenum-binding site.
+ 2 more references
💊

Medical Actions

9
Anticonvulsant therapy for seizures
Action: anticonvulsant agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is anticonvulsant agent therapy, annotated with Anticonvulsant Therapy (NCIT:C64172). NCIT:C64172 is a clinical intervention from the NCI Thesaurus. Ontology label: Anticonvulsant Therapy NCIT:C64172
Anti-seizure medication is the mainstay of symptomatic management, although the neonatal seizures of classic ISOD are characteristically pharmacoresistant — consistent with the mechanism, in which glutamatergic drive is increased and GABAergic inhibitory synapses are actively degraded.
Target Phenotypes: Neonatal seizure HP:0032807 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Neonatal seizure (HP:0032807). HP:0032807 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Symptomatic treatment can include: anti-seizure medication (ASM) for seizures; medications to reduce spasticity; and early consideration of gastrostomy tube placement to manage difficulties with swallowing, assure adequate caloric intake, and reduce risk of aspiration."
Documents anti-seizure medication as recommended symptomatic management.
Gastrostomy tube placement
Action: gastrostomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is gastrostomy (NCIT:C52006). NCIT:C52006 is a clinical intervention from the NCI Thesaurus. Ontology label: Gastrostomy NCIT:C52006
Early gastrostomy is recommended to manage swallowing difficulty, secure caloric intake and reduce aspiration risk.
Target Phenotypes: Feeding difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Symptomatic treatment can include: anti-seizure medication (ASM) for seizures; medications to reduce spasticity; and early consideration of gastrostomy tube placement to manage difficulties with swallowing, assure adequate caloric intake, and reduce risk of aspiration."
Documents early gastrostomy as recommended management of feeding difficulty.
Methionine- and cysteine-restricted diet
Action: dietary interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dietary intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
Dietary restriction of the sulfur amino acids methionine and cysteine aims to reduce the substrate load entering the blocked pathway. Reported benefit is limited and confined to late-presenting, milder patients: in a literature review of all published cases, clinical improvement on dietary therapy was seen in only two patients, both presenting after six months of age with relatively mild developmental delay. It is not effective in classic neonatal-onset disease.
Mechanism Target:
INHIBITS Sulfite Accumulation — Restricting dietary methionine and cysteine lowers the flux of sulfur amino acids entering catabolism upstream of the blocked step, reducing the rate at which sulfite is generated. The effect is inherently partial because cysteine is also supplied endogenously by protein turnover, which is the mechanistic reason dietary therapy helps only the mildest, later-presenting patients.
Show evidence (2 references)
PMID:16140720 SUPPORT Human Clinical
"Clinical improvement with dietary therapy was seen in only 2 patients, both of whom presented after the age of 6 months and had relatively mild developmental delays."
Supports a limited benefit of dietary therapy restricted to milder, later-presenting patients; classified PARTIAL because benefit was seen in only 2 of the reviewed cases.
PMID:16140720 SUPPORT Human Clinical
"The patient began a low-methionine and low-cysteine diet and was treated with thiamine and dextromethorphan."
Documents the composition of the dietary intervention used in ISOD.
Dextromethorphan
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: dextromethorphan CHEBI:4470 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dextromethorphan (CHEBI:4470). CHEBI:4470 is a therapeutic agent from Chemical Entities of Biological Interest.
Dextromethorphan is a non-competitive NMDA-receptor antagonist and is the clinical counterpart of the central excitotoxic mechanism: if S-sulfocysteine injures neurons by agonising the NMDA receptor, blocking that receptor should be protective. It has been given to ISOD patients alongside diet and thiamine, and a glutamatergic-receptor antagonist alleviates the SSC-induced seizure phenotype in zebrafish. No controlled human efficacy data exist, and the HUMAN_MODEL_MISMATCH discussion records a dissenting in-vitro report in which glutamate-receptor blockade failed to rescue SSC toxicity — so this is curated as a mechanism-motivated, unproven intervention rather than an effective therapy.
Mechanism Target:
INHIBITS NMDA Receptor Overactivation and Calcium Influx — NMDA-receptor antagonism is intended to block the proximal excitotoxic step — SSC-driven receptor overactivation and the calcium influx it gates — upstream of calpain activation and neuronal death.
Show evidence (3 references)
PMID:16140720 SUPPORT Human Clinical
"The patient began a low-methionine and low-cysteine diet and was treated with thiamine and dextromethorphan."
Documents clinical use of dextromethorphan in ISOD. Classified PARTIAL because the report establishes that the drug was administered but not that it altered the disease course.
PMID:31001109 SUPPORT Model Organism
"Seizure-like movements were fully revertible upon removal of SSC or could be alleviated by a glutamatergic receptor antagonist."
Provides the in vivo rationale — glutamatergic-receptor antagonism alleviates the SSC-induced seizure phenotype in zebrafish larvae.
PMID:39749013 REFUTE In Vitro
"The cytotoxic effects of SSC were not reversed by glutamate receptor blocker administration."
Directly challenges the rationale for receptor antagonism by showing a receptor-independent route to SSC cytotoxicity in HT-22 hippocampal cells. Retained so the therapeutic hypothesis is not presented as settled.
Sulfite scavenging (investigational)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: glutathione disulfide (oxidized glutathione) CHEBI:17858 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses glutathione disulfide (oxidized glutathione), annotated with glutathione disulfide (CHEBI:17858). CHEBI:17858 is a therapeutic agent from Chemical Entities of Biological Interest.
The first mechanism-based therapeutic concept for ISOD. Because the disease is driven by what accumulates rather than by what fails to be made, chemically removing sulfite should be disease-modifying regardless of the enzyme defect. Oxidized glutathione and glutathione trisulfide scavenge sulfite in vitro and in vivo and extend the lifespan of SOX-knockout mice. This is preclinical only — no human data exist — and is curated to record the mechanistic target, not an available therapy.
Mechanism Target:
INHIBITS Sulfite Accumulation — Scavengers react with sulfite directly, lowering its tissue concentration and therefore the formation of both downstream toxic products — S-sulfocysteine (the excitotoxic arm) and sulfite-driven persulfide stripping (the H2S arm). This is the one node at which a single intervention addresses both arms of the pathograph.
Show evidence (1 reference)
PMID:41178722 SUPPORT Model Organism
"oxidized glutathione and glutathione trisulfide were able to scavenge sulfite in vitro and in vivo, extending the lifespan of SOXD mice and providing a mechanistic concept of sulfite scavenging for the treatment of this severe metabolic disorder of cysteine catabolism."
Demonstrates sulfite scavenging and a survival benefit in the SOX-knockout mouse, establishing the mechanistic concept. Model-organism evidence only — no human efficacy is claimed.
Spasticity management
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Medications to reduce spasticity are part of the recommended symptomatic regimen for the spastic quadriplegia and abnormal tone of classic ISOD.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Symptomatic treatment can include: anti-seizure medication (ASM) for seizures; medications to reduce spasticity; and early consideration of gastrostomy tube placement to manage difficulties with swallowing, assure adequate caloric intake, and reduce risk of aspiration."
GeneReviews lists spasticity-reducing medication among recommended symptomatic measures.
Chest physiotherapy
Action: chest physiotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is chest physiotherapy, annotated with Physical Therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Vigorous chest physiotherapy is recommended to prevent the respiratory complications that follow from bulbar dysfunction and aspiration risk.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Other measures can include vigorous chest physiotherapy to prevent respiratory complications."
GeneReviews recommends vigorous chest physiotherapy for respiratory prophylaxis.
Supportive and multidisciplinary care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
No treatment exists for the underlying metabolic defect, so care is supportive: spasticity management, nutrition, respiratory care and periodic multidisciplinary surveillance of neurologic and nutritional status.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"No treatment exists for the underlying metabolic defect."
Establishes that management is symptomatic/supportive only.
Genetic counseling
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Autosomal recessive counseling with a 25% sibling recurrence risk; once the biallelic SUOX variants are known, carrier testing, prenatal testing and preimplantation genetic testing are available.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
Provides the recurrence risks that underpin genetic counseling.
🔬

Biochemical Markers

6
Urinary sulfite (INCREASED)
Context: Sulfite is detectable in fresh urine by dipstick and is the direct marker of the enzymatic block. The test is unreliable if the sample is not fresh, which is a documented cause of missed diagnosis.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
Documents dipstick-positive urinary sulfite as a diagnostic laboratory finding.
PMID:33335014 SUPPORT Human Clinical
"Missed diagnosis is not unusual because of variability in the sensitivity of the urinary sulfite and thiosulfate screening test."
Documents the limited sensitivity of the urinary sulfite screening test as a cause of missed diagnosis.
S-sulfocysteine (INCREASED)
Context: Elevated plasma and/or urinary S-sulfocysteine is the most consistent biochemical abnormality in ISOD, reported in every published case, and is simultaneously the proximate neurotoxin.
Show evidence (1 reference)
PMID:16140720 SUPPORT Human Clinical
"Plasma or urinary S-sulfocysteine levels were elevated in all cases."
Establishes S-sulfocysteine elevation as present in 100% of published cases.
Urinary thiosulfate (INCREASED)
Context: Thiosulfate is the second sulfite disposal product and is elevated in urine. In the SUOX-knockout mouse it accumulates 45-fold and is the major excreted sulfur metabolite.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
Documents elevated urinary thiosulfate in patients.
PMID:41178722 SUPPORT Model Organism
"Among the urinary biomarkers, thiosulfate showed a 45-fold accumulation in SOXD mice, representing the major excreted S-metabolite."
Quantifies thiosulfate as the dominant excreted sulfur metabolite in the knockout mouse.
Plasma total homocysteine (DECREASED)
Context: Markedly reduced — often undetectable — plasma total homocysteine is a counterintuitive but highly useful discriminator: most inborn errors on this pathway raise homocysteine, whereas ISOD lowers it.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
Documents markedly reduced plasma total homocysteine as a diagnostic clue.
PMID:16140720 SUPPORT Human Clinical
"Plasma total homocysteine was not detectable."
Case-level confirmation that plasma total homocysteine can be undetectable.
Plasma cystine (DECREASED)
Context: Plasma cystine falls because it is consumed in the non-enzymatic reaction with sulfite that generates S-sulfocysteine.
Show evidence (1 reference)
PMID:9050047 SUPPORT Human Clinical
"There was increased urine excretion of sulfite and S-sulfocysteine and a decreased concentration of plasma cystine."
Documents low plasma cystine alongside the sulfite/S-sulfocysteine elevation.
Plasma uric acid and urinary oxypurines (NORMAL)
Context: Normal uric acid and urinary oxypurines are what make the deficiency "isolated": they exclude molybdenum cofactor deficiency, in which xanthine dehydrogenase is also lost. This is the single most important discriminating test because MoCD type A is treatable and ISOD is not.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"Analysis of uric acid (plasma) and oxypurines (urine) is useful to rule out MoCD."
Establishes uric acid and urinary oxypurines as the tests that distinguish ISOD from MoCD.
🔬

Diagnosis

5
Urinary sulfite dipstick screening
A bedside dipstick positive for urinary sulfite is the fastest pointer to ISOD in a neonate with intractable seizures. It is a screening test only: sulfite is unstable and oxidises on standing, so a fresh sample is required and a negative result does not exclude the diagnosis. A positive dipstick does not distinguish ISOD from molybdenum cofactor deficiency, which produces the same secondary sulfite oxidase block.
laboratory test NCIT:C18020 NCI Thesaurus (NCIT)
Results: Dipstick positive for urinary sulfite in a fresh specimen supports ISOD or molybdenum cofactor deficiency.
Show evidence (1 reference)
PMID:28933809 SUPPORT Human Clinical
"Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
GeneReviews lists a positive urinary sulfite dipstick among the laboratory findings that suggest ISOD.
Sulfur metabolite panel (thiosulfate, S-sulfocysteine, organic sulfate, total homocysteine)
The biochemical signature of ISOD is a paired pattern: the sulfite disposal products rise while the oxidative end product and the transsulfuration pool fall. Elevated urinary thiosulfate and S-sulfocysteine with LOW urinary organic sulfate and markedly LOW plasma total homocysteine is close to specific. The low total homocysteine is the discriminating feature against the neighbouring sulfur amino acid disorders (CBS-deficient homocystinuria raises it), and is easy to misread as a normal or reassuring result.
laboratory test NCIT:C18020 NCI Thesaurus (NCIT)
Results: Elevated urinary thiosulfate and S-sulfocysteine with low urinary organic sulfate and markedly reduced plasma total homocysteine.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
Specifies the full suggestive metabolite panel, including the counterintuitive low organic sulfate and low total homocysteine.
PMID:16140720 SUPPORT Human Clinical
"Plasma or urinary S-sulfocysteine levels were elevated in all cases."
Establishes S-sulfocysteine elevation as an invariant finding across published cases, supporting its diagnostic sensitivity.
Discrimination from molybdenum cofactor deficiency
Because MoCD produces an identical secondary sulfite oxidase block, the metabolite panel alone cannot separate the two. The distinguishing test exploits the fact that ISOD spares the other molybdenum-cofactor-dependent enzymes: xanthine dehydrogenase activity and purine handling are normal in ISOD, so plasma uric acid and urinary xanthine/hypoxanthine are normal, whereas MoCD gives low uric acid with elevated xanthine. This distinction changes management, since MoCD type A is treatable with fosdenopterin and ISOD is not.
laboratory test NCIT:C18020 NCI Thesaurus (NCIT)
Results: Normal uric acid and normal urinary oxypurines indicate isolated sulfite oxidase deficiency rather than molybdenum cofactor deficiency.
Show evidence (1 reference)
PMID:9050047 SUPPORT Human Clinical
"Liver sulfite oxidase activity was not detectable but xanthine dehydrogenase activity was normal."
Demonstrates the enzymatic pattern that defines the isolated form — absent sulfite oxidase with preserved xanthine dehydrogenase, i.e. an intact molybdenum cofactor.
SUOX molecular genetic testing
Identification of biallelic pathogenic SUOX variants is the confirmatory test and the basis for subsequent carrier, prenatal and preimplantation genetic testing.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: Biallelic pathogenic SUOX variants confirm the diagnosis.
Show evidence (2 references)
PMID:28933809 SUPPORT Human Clinical
"The diagnosis is confirmed by identification of biallelic pathogenic variants in SUOX by molecular genetic testing."
GeneReviews states that molecular genetic testing provides diagnostic confirmation.
PMID:36303223 SUPPORT Human Clinical
"Isolated sulfite oxidase deficiency (ISOD) caused by sulfite oxidase gene (SUOX) mutations is a rare neurometabolic disease associated with ectopia lentis (EL)."
Supports SUOX sequencing as the route to diagnosis in patients ascertained through ectopia lentis rather than neonatal encephalopathy — the late-onset presentation most likely to be missed.
Brain MRI
Neuroimaging is abnormal in every ISOD patient imaged in the largest published review, typically showing diffuse cerebral atrophy, cystic encephalomalacia and ventriculomegaly. The pattern strongly resembles hypoxic-ischaemic injury, so imaging supports but does not establish the diagnosis and is a recognised route to misattributing ISOD to perinatal asphyxia.
magnetic resonance imaging NCIT:C16809 NCI Thesaurus (NCIT)
Results: Cerebral atrophy with cystic encephalomalacia and ventriculomegaly; mimics hypoxic-ischaemic encephalopathy.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"In all patients in whom brain magnetic resonance imaging/computed tomography (MRI/CT) was performed, brain abnormalities were found."
Establishes that structural brain abnormality is an invariant imaging finding in ISOD.
📊

Prevalence

1
Reported cases in the literature
Cases In Literature Ultra Rare
ISOD is ultra-rare. The most complete systematic review to date assembled only 47 patients worldwide.
Show evidence (1 reference)
PMID:28980090 SUPPORT Human Clinical
"We reviewed 47 patients (45 previously reported in the literature)."
Documents that fewer than 50 patients had been reported worldwide, consistent with an ultra-rare disorder.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Isolated Sulfite Oxidase Deficiency:

Molybdenum cofactor deficiency
Overlapping Features MoCD produces an identical secondary sulfite oxidase deficiency plus loss of xanthine dehydrogenase and aldehyde oxidase, and is clinically very similar at the bedside. The distinction is critical because MoCD type A is treatable whereas ISOD is not.
Distinguishing Features
  • Plasma uric acid and urinary oxypurines are normal in ISOD but abnormal in MoCD, reflecting the additional loss of xanthine dehydrogenase in MoCD.
  • Direct liver enzyme assay shows absent sulfite oxidase with normal xanthine dehydrogenase activity in ISOD.
Show evidence (3 references)
PMID:16140720 SUPPORT Human Clinical
"The main alternative in the differential diagnosis of isolated sulfite oxidase deficiency is molybdenum cofactor deficiency."
Identifies MoCD as the principal differential diagnosis.
PMID:28980090 SUPPORT Human Clinical
"As no long-term effective treatment is available, distinction from other treatable diseases, such as molybdenum cofactor deficiency (MoCD) type A, should be made."
States why the distinction matters clinically — MoCD type A is treatable and ISOD is not.
PMID:9050047 SUPPORT Human Clinical
"Liver sulfite oxidase activity was not detectable but xanthine dehydrogenase activity was normal."
Documents the enzymatic pattern that distinguishes ISOD from MoCD.
{ }

Source YAML

click to show 
name: Isolated Sulfite Oxidase Deficiency
category: Mendelian
creation_date: '2026-07-31T00:00:00Z'
synonyms:
- ISOD
- Sulfocysteinuria
- SUOX deficiency
- Sulfite oxidase deficiency, isolated
description: >
  Isolated sulfite oxidase deficiency (ISOD) is an ultra-rare, autosomal recessive
  inborn error of sulfur (cysteine) catabolism caused by biallelic loss-of-function
  variants in SUOX. SUOX encodes sulfite oxidase, the molybdenum-cofactor- and
  heme-dependent enzyme of the mitochondrial intermembrane space that catalyses the
  terminal step of sulfur amino acid degradation, oxidising sulfite to sulfate. When
  the enzyme is lost, sulfite accumulates and is shunted into two diagnostic
  metabolites: S-sulfocysteine, formed by reaction of sulfite with cystine, and
  thiosulfate. S-sulfocysteine is a structural analog of glutamate and behaves as an
  NMDA-receptor agonist, so the accumulating metabolite is not merely a marker but
  the proximate neurotoxin — it drives calcium influx, calpain activation and
  calpain-dependent degradation of the inhibitory postsynaptic scaffold gephyrin,
  simultaneously raising excitatory drive and stripping GABAergic inhibition. The
  resulting excitotoxic injury produces the characteristic clinical picture: classic
  ISOD presents in the first hours to days of life with pharmacoresistant seizures,
  feeding difficulty and rapidly progressive encephalopathy with opisthotonus and
  spastic quadriplegia, followed by progressive microcephaly, profound intellectual
  disability, cerebral atrophy with cystic encephalomalacia, and death in infancy. A
  milder late-onset form manifests between six and 18 months with ectopia lentis, a
  dystonic-choreoathetotic movement disorder and developmental regression, and is
  associated with biallelic missense genotypes that retain residual activity. Lens
  subluxation or dislocation is a hallmark at any severity. Because the same
  metabolic block occurs downstream of molybdenum cofactor deficiency (MoCD), which
  additionally impairs xanthine dehydrogenase, distinguishing ISOD from MoCD by uric
  acid and urinary oxypurines is diagnostically essential — MoCD type A is treatable
  whereas no disease-modifying therapy exists for ISOD.
disease_term:
  preferred_term: isolated sulfite oxidase deficiency
  term:
    id: MONDO:0010089
    label: isolated sulfite oxidase deficiency
parents:
- Metabolic Disease
- Inborn Error of Metabolism
classifications:
  icimd_category:
  - classification_value: sulfur_containing_amino_acids
    notes: >-
      ICIMD: ISOD is a disorder of the metabolism of sulfur-containing amino acids —
      SUOX encodes the terminal oxidative enzyme of cysteine catabolism. Curated as
      IEMbase row 1.5.09.01 of package WP-002 ("Disorders of the metabolism of
      sulfur-containing amino acids and hydrogen sulfide").
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010089
      label: isolated sulfite oxidase deficiency
    mapping_predicate: skos:exactMatch
    mapping_source: OMIM:272300
    mapping_justification: >
      MONDO:0010089 (isolated sulfite oxidase deficiency) cross-references
      OMIM:272300 and Orphanet:99731 and declares SUOX (HGNC:11460) as its causal
      gene, matching the gene and OMIM identifier of the curated entity.
inheritance:
- name: Autosomal recessive
  description: >
    ISOD is caused by biallelic pathogenic SUOX variants. Heterozygous parents are
    asymptomatic obligate carriers; each sibling of a proband has a 25% recurrence
    risk.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ISOD is inherited in an autosomal recessive manner."
    explanation: GeneReviews states the autosomal recessive mode of inheritance.
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis is confirmed by identification of biallelic pathogenic variants in SUOX by molecular genetic testing."
    explanation: Confirms that biallelic SUOX variants define the molecular diagnosis.
prevalence:
- population: Reported cases in the literature
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    ISOD is ultra-rare. The most complete systematic review to date assembled only 47
    patients worldwide.
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We reviewed 47 patients (45 previously reported in the literature)."
    explanation: Documents that fewer than 50 patients had been reported worldwide, consistent with an ultra-rare disorder.
has_subtypes:
- name: Classic ISOD
  display_name: Classic early-onset (severe) ISOD
  description: >
    Neonatal-onset severe form presenting in the first hours to days of life with
    intractable seizures, feeding difficulties and rapidly progressive encephalopathy
    with opisthotonus and spastic quadriplegia, followed by progressive microcephaly,
    profound intellectual disability and death in infancy.
  genes:
  - preferred_term: SUOX
    term:
      id: hgnc:11460
      label: SUOX
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability."
    explanation: Defines the classic early-onset severe subtype.
- name: Late-onset ISOD
  display_name: Late-onset (mild) ISOD
  description: >
    Milder form manifesting between six and 18 months of age with variably present
    ectopia lentis, developmental delay or regression, a movement disorder of
    dystonia and choreoathetosis, ataxia and rarely metabolic stroke. The course may
    be progressive or episodic. Biallelic missense genotypes are enriched in this
    presentation.
  genes:
  - preferred_term: SUOX
    term:
      id: hgnc:11460
      label: SUOX
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
    explanation: Defines the late-onset milder subtype and its distinguishing movement-disorder phenotype.
  - reference: PMID:36303223
    reference_title: "Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "suggest that missense mutations are associated with mild and atypical symptoms"
    explanation: Links the milder/atypical presentations to biallelic missense genotypes.
mechanistic_hypotheses:
- hypothesis_group_id: zonular_disulfide_reduction
  hypothesis_label: Sulfite-Mediated Zonular Disulfide Reduction
  status: EMERGING
  description: >-
    The widely repeated explanation for ectopia lentis in ISOD is that sulfite, a
    nucleophilic anion, reduces the disulfide bonds cross-linking the fibrillin-rich
    zonular fibres that suspend the lens, weakening them until the lens subluxes. It
    is chemically plausible and would explain the phenotypic convergence with
    homocystinuria and Marfan syndrome, where zonular integrity also fails. However,
    no primary study demonstrating the step in ISOD (or SUOX-deficient) zonular tissue
    was identified during curation, so the causal edge from Sulfite Accumulation to
    Ectopia Lentis is typed INDIRECT_UNKNOWN_INTERMEDIATES and opted into this group
    rather than presented as established. See the `ectopia_lentis_mechanism_unresolved`
    discussion for the experiments that would resolve it.
  notes: >-
    Status EMERGING rather than CANONICAL deliberately: the clinical association is
    solid, the mechanism is not.
pathophysiology:
- name: SUOX Sulfite Oxidase Deficiency
  description: >
    Biallelic loss-of-function variants in SUOX abolish the activity of sulfite
    oxidase, the molybdenum-cofactor- and heme-containing homodimeric enzyme of the
    mitochondrial intermembrane space that catalyses the terminal, irreversible step
    of sulfur amino acid catabolism — oxidation of sulfite to sulfate. Because the
    lesion is confined to SUOX itself, the other molybdenum-cofactor-dependent
    enzymes (notably xanthine dehydrogenase) remain intact, which is the biochemical
    basis for distinguishing ISOD from molybdenum cofactor deficiency.
  role: trigger
  biological_scale: MOLECULAR
  genes:
  - preferred_term: SUOX
    term:
      id: hgnc:11460
      label: SUOX
  molecular_functions:
  - preferred_term: sulfite oxidase activity
    term:
      id: GO:0008482
      label: sulfite oxidase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: sulfur amino acid catabolic process
    term:
      id: GO:0000098
      label: sulfur amino acid catabolic process
    modifier: DECREASED
  - preferred_term: L-cysteine catabolic process
    term:
      id: GO:0019448
      label: L-cysteine catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:33335014
    reference_title: "Isolated sulfite oxidase deficiency: a founder mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Isolated sulfite oxidase deficiency is a rare autosomal recessive inborn error of sulfur metabolism."
    explanation: Establishes ISOD as a recessive inborn error of sulfur metabolism.
  - reference: PMID:9050047
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver sulfite oxidase activity was not detectable but xanthine dehydrogenase activity was normal."
    explanation: >-
      Demonstrates the defining enzymatic signature of the isolated form — absent
      sulfite oxidase activity with preserved xanthine dehydrogenase, i.e. an intact
      molybdenum cofactor.
  - reference: PMID:41178722
    reference_title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Sulfite oxidase (SOX) deficiency is a rare inborn error of cysteine metabolism resulting in severe neurological damage."
    explanation: >-
      Places the enzymatic lesion within cysteine catabolism and links it to the
      neurological outcome. Tagged MODEL_ORGANISM because this is the framing
      sentence of a full-body SOX-knockout mouse study rather than a human
      observation; the human evidence for the same claim is the preceding two
      items.
  downstream:
  - target: Sulfite Accumulation
    description: >
      Loss of the terminal oxidative step leaves sulfite, generated continuously from
      dietary and endogenous cysteine catabolism, without a route to sulfate, so it
      accumulates to toxic concentrations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28933809
      reference_title: "Isolated Sulfite Oxidase Deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
      explanation: >-
        Human evidence that the enzymatic block leaves sulfite accumulating —
        urinary sulfite is dipstick positive and its secondary disposal products
        (thiosulfate, S-sulfocysteine) are elevated while organic sulfate output
        falls.
    - reference: PMID:41178722
      reference_title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In patients, sulfite accumulates to toxic levels, causing a rise in the downstream products S-sulfocysteine, which mediates excitotoxicity, and thiosulfate, a catabolic intermediate/product of hydrogen sulfide (H2S) metabolism."
      explanation: >-
        States that loss of sulfite oxidase causes toxic sulfite accumulation.
        Tagged MODEL_ORGANISM because the sentence is introductory framing in a
        SOX-knockout mouse study, not data generated in human patients.
- name: Sulfite Accumulation
  description: >
    Sulfite, a reactive nucleophilic anion, accumulates in tissues and body fluids.
    It is disposed of by two secondary routes that generate the diagnostic
    metabolites of ISOD: reaction with cystine to form S-sulfocysteine, and
    conversion to thiosulfate. The diversion of cystine into S-sulfocysteine also
    contributes to the paradoxical fall in plasma cystine, and organic sulfate output
    falls because the oxidative route to sulfate is blocked.
  role: amplifier
  biological_scale: MOLECULAR
  chemical_entities:
  - preferred_term: sulfite
    term:
      id: CHEBI:17359
      label: sulfite
    modifier: INCREASED
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
    explanation: >-
      Documents the full biochemical consequence of the block — sulfite, thiosulfate
      and S-sulfocysteine accumulation with low organic sulfate and low total
      homocysteine.
  downstream:
  - target: S-Sulfocysteine Accumulation
    description: >
      Sulfite reacts with cystine to generate S-sulfocysteine, which is elevated in
      plasma and urine of every reported patient.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16140720
      reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Plasma or urinary S-sulfocysteine levels were elevated in all cases."
      explanation: Establishes S-sulfocysteine accumulation as an invariant consequence across all published cases.
  - target: Ectopia Lentis
    description: >
      Accumulating sulfite is presumed to reach the ocular zonule and compromise the
      disulfide-rich fibrillin microfibrils that suspend the lens. The intermediates
      are unknown and no primary study establishes the step in ISOD tissue, so the
      edge is typed INDIRECT_UNKNOWN_INTERMEDIATES and assigned to the
      `zonular_disulfide_reduction` hypothesis group rather than asserted as an
      evidenced mechanism. Its evidence is the clinical co-occurrence only.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - zonular_disulfide_reduction
    evidence:
    - reference: PMID:36303223
      reference_title: "Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Isolated sulfite oxidase deficiency (ISOD) caused by sulfite oxidase gene (SUOX) mutations is a rare neurometabolic disease associated with ectopia lentis (EL)."
      explanation: >-
        Supports the disease-level association between SUOX deficiency and ectopia
        lentis. Classified PARTIAL because it establishes that the two co-occur, not
        that sulfite accumulation causes zonular failure.
  - target: Loss of Protein S-Persulfidation and Hydrogen Sulfide Release
    description: >
      Accumulating sulfite reacts with protein persulfides, releasing hydrogen
      sulfide and stripping the persulfide post-translational modification from a
      large fraction of the proteome.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41178722
      reference_title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Consistently, we found increased plasma H2S, which was derived from sulfite-induced release from persulfides, as demonstrated in vitro and in vivo."
      explanation: Demonstrates that accumulated sulfite liberates H2S from protein persulfides in the SOX-knockout mouse.
- name: S-Sulfocysteine Accumulation
  description: >
    S-sulfocysteine (SSC) is a structural analog of glutamate. Its accumulation
    converts the metabolic block into a neurochemical lesion, because SSC is not an
    inert marker but an agonist at ionotropic glutamate receptors.
  role: amplifier
  biological_scale: MOLECULAR
  chemical_entities:
  - preferred_term: S-sulfo-L-cysteine
    term:
      id: CHEBI:62225
      label: S-sulfo-L-cysteinate(1-)
    modifier: INCREASED
  evidence:
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasma or urinary S-sulfocysteine levels were elevated in all cases."
    explanation: >-
      Human evidence that S-sulfocysteine accumulates in every reported ISOD
      patient, establishing the metabolite elevation itself.
  - reference: PMID:31001109
    reference_title: "S-Sulfocysteine Induces Seizure-Like Behaviors in Zebrafish."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In humans, SOX deficiency causes the formation of the glutamate analog S-Sulfocysteine (SSC) resulting in a constant overstimulation of ionotropic glutamatergic receptors."
    explanation: >-
      Frames the accumulating SSC as a glutamate analog that overstimulates
      ionotropic glutamate receptors. Tagged MODEL_ORGANISM because the sentence
      is introductory framing in a zebrafish study, not human data; the human
      metabolite evidence is the preceding item.
  downstream:
  - target: NMDA Receptor Overactivation and Calcium Influx
    description: >
      SSC acts as an NMDA-receptor agonist, producing calcium influx and downstream
      excitotoxic signalling.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29106383
      reference_title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "demonstrated that it acts as an N-methyl D-aspartate receptor (NMDA-R) agonist, leading to calcium influx and downstream cell signaling events and neurotoxicity"
      explanation: >-
        Demonstrates SSC agonism at the NMDA receptor with calcium influx and
        neurotoxicity. Shown for SSC accumulating in molybdenum cofactor deficiency,
        which shares the sulfite-oxidase block with ISOD.
- name: NMDA Receptor Overactivation and Calcium Influx
  description: >
    SSC, a structural analog of glutamate, acts as an agonist at the NMDA receptor.
    The resulting receptor overactivation opens the associated cation conductance and
    loads the neuron with calcium — the proximal molecular event of the excitotoxic
    arm. Receptor activation and the calcium entry it gates are curated as one node
    because they are a single pharmacologically inseparable step: blocking either the
    receptor or the calcium influx abolishes the toxicity equally.
  role: central_effector
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: NMDA glutamate receptor activity
    term:
      id: GO:0004972
      label: NMDA glutamate receptor activity
    modifier: INCREASED
  biological_processes:
  - preferred_term: calcium ion import
    term:
      id: GO:0070509
      label: calcium ion import
    modifier: INCREASED
  evidence:
  - reference: PMID:29106383
    reference_title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "demonstrated that it acts as an N-methyl D-aspartate receptor (NMDA-R) agonist, leading to calcium influx and downstream cell signaling events and neurotoxicity"
    explanation: >-
      Establishes SSC agonism at the NMDA receptor and the calcium influx it gates.
  downstream:
  - target: Calpain Activation and Gephyrin Degradation
    description: >
      Calcium loading activates the calcium-dependent protease calpain, which
      proteolyses the inhibitory postsynaptic scaffold gephyrin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29106383
      reference_title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Pharmacological blockade of NMDA-R, calcium influx, or calpain activity abolished SSC and glutamate neurotoxicity in primary murine neurons."
      explanation: >-
        Blocking the receptor, the calcium influx, or calpain each abolishes the
        toxicity, establishing that calpain activation lies causally downstream of
        NMDA-R-gated calcium entry rather than merely accompanying it.
  - target: Excitotoxic Neuronal Death and Cystic Encephalomalacia
    description: >
      Sustained excitotoxic calcium loading kills neurons; in the neonatal brain the
      resulting injury is severe enough to cavitate, producing cortical necrosis and
      cystic white matter change.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31001109
      reference_title: "S-Sulfocysteine Induces Seizure-Like Behaviors in Zebrafish."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "SSC induces increased swimming, seizure-like movements, and increased cell death in the central nervous system of zebrafish larvae"
      explanation: >-
        Shows in vivo that SSC alone is sufficient to cause both seizure-like
        behaviour and CNS cell death.
- name: Calpain Activation and Gephyrin Degradation
  description: >
    Calcium-activated calpain degrades gephyrin, the scaffold protein that clusters
    and anchors glycine and GABA-A receptors at inhibitory postsynapses. This is the
    step that converts a glutamatergic insult into an inhibitory-synapse lesion, and
    is why the excitation/inhibition shift in ISOD is two-directional rather than
    purely excitatory.
  role: amplifier
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: calcium-dependent cysteine-type endopeptidase activity
    term:
      id: GO:0004198
      label: calcium-dependent cysteine-type endopeptidase activity
    modifier: INCREASED
  biological_processes:
  - preferred_term: protein catabolic process
    term:
      id: GO:0030163
      label: protein catabolic process
    modifier: INCREASED
  evidence:
  - reference: PMID:29106383
    reference_title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SSC treatment activated the protease calpain, and calpain-dependent degradation of the inhibitory synaptic protein gephyrin subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic synapses."
    explanation: >-
      Demonstrates calpain activation by SSC and calpain-dependent proteolysis of
      gephyrin.
  downstream:
  - target: Loss of GABAergic Inhibition
    description: >
      Loss of the gephyrin scaffold disperses GABA-A receptor clusters and destroys
      inhibitory synapses, reducing GABAergic signalling.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29106383
      reference_title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "calpain-dependent degradation of the inhibitory synaptic protein gephyrin subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic synapses"
      explanation: >-
        Links gephyrin proteolysis directly to loss of GABAergic synapses and to
        amplification of the excitotoxicity.
- name: Loss of GABAergic Inhibition
  description: >
    Destruction of inhibitory synapses lowers GABAergic tone. Combined with the
    raised glutamatergic drive upstream, ISOD shifts the excitation/inhibition
    balance from both directions at once — increased excitation plus actively
    destroyed inhibition — which is a mechanistic explanation for the
    pharmacoresistance of the neonatal seizures, since most anti-seizure medications
    act by potentiating the very GABAergic synapses that are being lost.
  role: central_effector
  biological_scale: CELLULAR
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: GABAergic Neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABA Signaling Pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  - preferred_term: GABA-A receptor clustering
    term:
      id: GO:0097112
      label: gamma-aminobutyric acid receptor clustering
    modifier: DECREASED
  evidence:
  - reference: PMID:29106383
    reference_title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SSC treatment activated the protease calpain, and calpain-dependent degradation of the inhibitory synaptic protein gephyrin subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic synapses."
    explanation: >-
      Establishes loss of GABAergic synapses as the endpoint of the calpain-gephyrin
      arm and shows that it feeds back to exacerbate the excitotoxicity.
  downstream:
  - target: Neonatal Epileptic Encephalopathy
    description: >
      The excitation/inhibition imbalance manifests clinically as intractable
      neonatal seizures with rapidly progressive encephalopathy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31001109
      reference_title: "S-Sulfocysteine Induces Seizure-Like Behaviors in Zebrafish."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Seizure-like movements were fully revertible upon removal of SSC or could be alleviated by a glutamatergic receptor antagonist."
      explanation: >-
        Demonstrates that the seizure phenotype is directly attributable to SSC acting
        at glutamatergic receptors and is reversible when that drive is removed.
- name: Loss of Protein S-Persulfidation and Hydrogen Sulfide Release
  description: >
    A second, more recently defined arm of the pathophysiology: accumulating sulfite
    strips persulfide groups from cysteine residues across the proteome, releasing
    hydrogen sulfide and abolishing a redox-relevant post-translational modification
    on enzymes of amino acid and fatty acid metabolism and of cytosolic iron-sulfur
    cluster biogenesis. This connects ISOD to the wider hydrogen sulfide disorders
    (compare ETHE1 deficiency) and provides a mechanistic rationale for sulfite
    scavenging as therapy.
  role: amplifier
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:41178722
    reference_title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mass spectrometry analysis of total protein persulfidome identified a major loss of S-persulfidation in 20% of the proteome, affecting enzymes in amino acids, fatty acid metabolism, and cytosolic iron-sulfur cluster biogenesis."
    explanation: Quantifies the proteome-wide loss of persulfidation in the SOX-knockout mouse.
  downstream:
  - target: Mitochondrial Dysfunction and Metabolic Rewiring
    description: >
      Loss of persulfidation across metabolic enzymes is accompanied by an altered
      urinary amino acid profile indicating metabolic rewiring and mitochondrial
      dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:41178722
      reference_title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Urinary amino acid profiles indicated metabolic rewiring and mitochondrial dysfunction, thus identifying an altered H2S metabolism and persulfidation in SOXD."
      explanation: Links the persulfidation defect to mitochondrial dysfunction and metabolic rewiring.
- name: Mitochondrial Dysfunction and Metabolic Rewiring
  description: >
    Secondary bioenergetic failure. Human neuropathology in ISOD — cortical necrosis
    with extensive cavitating leukoencephalopathy resembling perinatal asphyxia — has
    long been read as evidence that an energy-deficiency component contributes
    alongside excitotoxicity.
  role: amplifier
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:9050047
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuropathological findings of cortical necrosis and extensive cavitating leukoencephalopathy were reminiscent of those seen in severe perinatal asphyxia suggesting an etiology of energy deficiency."
    explanation: >-
      Human autopsy findings interpreted by the authors as indicating an
      energy-deficiency contribution to the brain injury.
  downstream:
  - target: Excitotoxic Neuronal Death and Cystic Encephalomalacia
    description: >
      Bioenergetic compromise lowers the threshold for excitotoxic injury and
      contributes to the cavitating pattern of destruction.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:9050047
      reference_title: "Isolated sulfite oxidase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neuropathological findings of cortical necrosis and extensive cavitating leukoencephalopathy were reminiscent of those seen in severe perinatal asphyxia suggesting an etiology of energy deficiency."
      explanation: >-
        Supports the association of energy deficiency with the cavitating necrotic
        lesion, but the causal intermediates between bioenergetic failure and the
        specific lesion pattern are not established.
- name: Excitotoxic Neuronal Death and Cystic Encephalomalacia
  description: >
    Neuronal death in the immature brain produces the imaging and neuropathological
    signature of ISOD — diffuse cerebral (and cerebellar) atrophy, cystic white
    matter change and ventriculomegaly — found in every patient imaged in the largest
    published review.
  role: consequence
  biological_scale: TISSUE
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebral atrophy and cystic encephalomalacia were observed with neuroradiologic imaging and were noted in all 3 postmortem reports of isolated sulfite oxidase deficiency."
    explanation: Documents cerebral atrophy and cystic encephalomalacia on imaging and at autopsy.
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all patients in whom brain magnetic resonance imaging/computed tomography (MRI/CT) was performed, brain abnormalities were found."
    explanation: Establishes that structural brain injury is an invariant finding in imaged patients.
  downstream:
  - target: Progressive Microcephaly and Profound Neurodevelopmental Impairment
    description: >
      Ongoing destruction of brain parenchyma from birth produces acquired,
      progressive microcephaly and profound intellectual disability.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28933809
      reference_title: "Isolated Sulfite Oxidase Deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability."
      explanation: Places progressive microcephaly and profound intellectual disability downstream of the progressive encephalopathy.
- name: Neonatal Epileptic Encephalopathy
  description: >
    The clinical presentation of the excitation/inhibition lesion: pharmacoresistant
    seizures beginning within the first 72 hours of life in most patients, with axial
    hypotonia, peripheral hypertonia, opisthotonus and feeding difficulty.
  role: consequence
  biological_scale: ORGANISM
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Onset occurred mostly during the first 72 h of life (57%) and within the first year of life in all but two patients (96%)."
    explanation: Establishes the neonatal/early-infantile onset of the encephalopathy.
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
    explanation: Quantifies the neurological presentation, including pharmacoresistant seizures in 84% of patients.
  downstream:
  - target: Death in Infancy
    description: >
      In the classic form the encephalopathy is rapidly fatal.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28933809
      reference_title: "Isolated Sulfite Oxidase Deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Children usually die during the first few months of life."
      explanation: States the fatal outcome of classic ISOD.
- name: Progressive Microcephaly and Profound Neurodevelopmental Impairment
  description: >
    Acquired progressive microcephaly with profound intellectual disability and
    spastic quadriplegia, the end state of the destructive encephalopathy in
    survivors of the neonatal period.
  role: consequence
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
    explanation: Documents developmental delay in 97% of reported patients.
- name: Death in Infancy
  description: >
    Classic ISOD is usually fatal within the first months of life; the milder
    late-onset form is compatible with longer survival.
  role: consequence
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Children usually die during the first few months of life."
    explanation: Documents the usual fatal outcome of classic ISOD in infancy.
- name: Ectopia Lentis
  description: >
    Subluxation or frank dislocation of the ocular lens is the characteristic
    extraneurological feature of ISOD and may be the presenting sign in the milder
    late-onset form, sometimes with otherwise minimal neurological involvement. It
    typically becomes evident after the newborn period. The mechanism is presumed to
    involve sulfite-mediated damage to the disulfide-rich zonular fibres that suspend
    the lens, but this remains a hypothesis rather than a demonstrated step (see
    discussions).
  role: consequence
  biological_scale: TISSUE
  locations:
  - preferred_term: lens of camera-type eye
    term:
      id: UBERON:0000965
      label: lens of camera-type eye
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lens subluxation or dislocation, another characteristic finding, may be evident after the newborn period."
    explanation: Documents lens subluxation/dislocation as a characteristic finding appearing after the newborn period.
  - reference: PMID:36303223
    reference_title: "Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Isolated sulfite oxidase deficiency (ISOD) caused by sulfite oxidase gene (SUOX) mutations is a rare neurometabolic disease associated with ectopia lentis (EL)."
    explanation: Confirms the ISOD-ectopia lentis association in a cohort ascertained through congenital ectopia lentis.
phenotypes:
- name: Neonatal seizure
  category: Neurologic
  description: >
    Pharmacoresistant seizures, typically beginning within the first 72 hours of
    life, are the cardinal presenting feature.
  phenotype_term:
    preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
  diagnostic: true
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
    explanation: >-
      Reports (pharmacoresistant) seizures in 84% of 47 reviewed patients. No
      `frequency` band is asserted here: the 84% figure counts seizures at any
      age, whereas this phenotype is the neonatal-onset term (HP:0032807), for
      which the source reports 57% (first 72 h). Per
      docs/frequency-evidence-guidelines.md the band is omitted rather than
      derived from a non-matching denominator.
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Onset occurred mostly during the first 72 h of life (57%) and within the first year of life in all but two patients (96%)."
    explanation: Establishes the neonatal timing of onset.
- name: Axial hypotonia
  category: Neurologic
  description: >
    Neonatal axial hypotonia, usually combined with peripheral hypertonia, was
    present in every reviewed patient.
  phenotype_term:
    preferred_term: Axial hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
    explanation: >-
      Documents neonatal axial hypotonia as part of the invariant neurological
      presentation. No `frequency` band is asserted: the reported 100% covers the
      disjunction "axial hypotonia and/or peripheral hypertonia", so it does not
      quantify axial hypotonia on its own, and per
      docs/frequency-evidence-guidelines.md the band is omitted rather than
      inferred from a compound denominator.
- name: Hypertonia
  category: Neurologic
  description: Peripheral hypertonia accompanies the axial hypotonia in the neonatal period.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
    explanation: Peripheral hypertonia is reported as part of the invariant neurological presentation.
- name: Opisthotonus
  category: Neurologic
  description: Opisthotonic posturing is characteristic of the rapidly progressive classic encephalopathy.
  subtype: Classic ISOD
  phenotype_term:
    preferred_term: Opisthotonus
    term:
      id: HP:0002179
      label: Opisthotonus
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability."
    explanation: Lists opisthotonus among the characteristic tone abnormalities of classic ISOD.
- name: Spastic tetraplegia
  category: Neurologic
  description: Spastic quadriplegia with pyramidal signs develops as the encephalopathy progresses.
  subtype: Classic ISOD
  phenotype_term:
    preferred_term: Spastic tetraplegia
    term:
      id: HP:0002510
      label: Spastic tetraplegia
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability."
    explanation: Documents spastic quadriplegia and pyramidal signs in classic ISOD.
- name: Global developmental delay
  category: Neurologic
  description: Developmental delay was reported in nearly all reviewed patients.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented with neurological abnormalities, such as neonatal axial hypotonia and/or peripheral hypertonia (100%), (pharmacoresistant) seizures (84%), or developmental delay (97%)."
    explanation: >-
      Reports developmental delay in 97% of reviewed patients, supporting the
      VERY_FREQUENT (80-99%) frequency band.
- name: Progressive microcephaly
  category: Neurologic
  description: >
    Microcephaly is acquired and progressive, reflecting ongoing destruction of brain
    parenchyma rather than a primary defect of brain growth.
  subtype: Classic ISOD
  phenotype_term:
    preferred_term: Progressive microcephaly
    term:
      id: HP:0000253
      label: Progressive microcephaly
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability."
    explanation: Documents progressive microcephaly following the neonatal encephalopathy.
- name: Profound intellectual disability
  category: Neurologic
  description: Survivors of the neonatal presentation have profound intellectual disability.
  subtype: Classic ISOD
  phenotype_term:
    preferred_term: Profound intellectual disability
    term:
      id: HP:0002187
      label: Profound intellectual disability
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability."
    explanation: Documents profound intellectual disability as an outcome of classic ISOD.
- name: Feeding difficulties
  category: Gastrointestinal
  description: >
    Feeding and swallowing difficulty is common from the neonatal period and often
    prompts gastrostomy placement.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability."
    explanation: Lists feeding difficulties among the presenting features of classic ISOD.
- name: Ectopia lentis
  category: Ophthalmologic
  description: >
    Lens subluxation or dislocation, typically appearing after the newborn period,
    and sometimes the presenting sign in late-onset disease.
  phenotype_term:
    preferred_term: Ectopia lentis
    term:
      id: HP:0001083
      label: Ectopia lentis
  diagnostic: true
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lens subluxation or dislocation, another characteristic finding, may be evident after the newborn period."
    explanation: Documents ectopia lentis as a characteristic finding.
  - reference: PMID:33335014
    reference_title: "Isolated sulfite oxidase deficiency: a founder mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical features generally include devastating neurologic dysfunction, ectopia lentis, and increased urinary excretion of sulfite, thiosulfate, and S-sulfocysteine."
    explanation: Lists ectopia lentis among the general clinical features of ISOD.
- name: Dystonia
  category: Neurologic
  description: A dystonic-choreoathetotic movement disorder characterizes the late-onset form.
  subtype: Late-onset ISOD
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
    explanation: Documents dystonia as part of the late-onset movement disorder.
- name: Choreoathetosis
  category: Neurologic
  description: Choreoathetosis accompanies dystonia in the late-onset form.
  subtype: Late-onset ISOD
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
    explanation: Documents choreoathetosis in the late-onset form.
- name: Ataxia
  category: Neurologic
  description: Ataxia is part of the late-onset movement-disorder phenotype.
  subtype: Late-onset ISOD
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
    explanation: Documents ataxia in the late-onset form.
- name: Developmental regression
  category: Neurologic
  description: >
    Developmental regression, sometimes episodic, characterizes late-onset disease and
    is more often reported in patients with biallelic missense genotypes.
  subtype: Late-onset ISOD
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
    explanation: Documents developmental delay/regression in the late-onset form.
- name: Hemiparesis
  category: Neurologic
  description: Acute hemiplegia from metabolic stroke is a rare manifestation of late-onset disease.
  subtype: Late-onset ISOD
  phenotype_term:
    preferred_term: Hemiparesis
    term:
      id: HP:0001269
      label: Hemiparesis
  frequency: VERY_RARE
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia as a result of metabolic stroke."
    explanation: >-
      Describes acute hemiplegia as a rare ("(rarely)") manifestation, supporting the
      VERY_RARE frequency band.
- name: Cerebral atrophy
  category: Neurologic
  description: Diffuse cerebral atrophy is seen on neuroimaging and at autopsy.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebral atrophy and cystic encephalomalacia were observed with neuroradiologic imaging and were noted in all 3 postmortem reports of isolated sulfite oxidase deficiency."
    explanation: Documents cerebral atrophy on imaging and at postmortem.
- name: Cerebellar atrophy
  category: Neurologic
  description: Cerebellar atrophy is among the reported radiological findings.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "radiological findings (including cerebral/cerebellar atrophy, cystic white matter changes, ventriculomegaly)"
    explanation: Lists cerebellar atrophy among the radiological findings reviewed.
- name: Leukoencephalopathy
  category: Neurologic
  description: >
    Cystic white matter change, described neuropathologically as extensive cavitating
    leukoencephalopathy.
  phenotype_term:
    preferred_term: Leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
  evidence:
  - reference: PMID:9050047
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuropathological findings of cortical necrosis and extensive cavitating leukoencephalopathy were reminiscent of those seen in severe perinatal asphyxia suggesting an etiology of energy deficiency."
    explanation: Documents extensive cavitating leukoencephalopathy at autopsy.
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "radiological findings (including cerebral/cerebellar atrophy, cystic white matter changes, ventriculomegaly)"
    explanation: Lists cystic white matter changes among the radiological findings reviewed.
- name: Ventriculomegaly
  category: Neurologic
  description: Ventriculomegaly follows the loss of brain parenchyma.
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "radiological findings (including cerebral/cerebellar atrophy, cystic white matter changes, ventriculomegaly)"
    explanation: Lists ventriculomegaly among the radiological findings reviewed.
biochemical:
- name: Urinary sulfite
  presence: INCREASED
  context: >
    Sulfite is detectable in fresh urine by dipstick and is the direct marker of the
    enzymatic block. The test is unreliable if the sample is not fresh, which is a
    documented cause of missed diagnosis.
  biomarker_term:
    preferred_term: sulfite
    term:
      id: CHEBI:17359
      label: sulfite
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
    explanation: Documents dipstick-positive urinary sulfite as a diagnostic laboratory finding.
  - reference: PMID:33335014
    reference_title: "Isolated sulfite oxidase deficiency: a founder mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Missed diagnosis is not unusual because of variability in the sensitivity of the urinary sulfite and thiosulfate screening test."
    explanation: Documents the limited sensitivity of the urinary sulfite screening test as a cause of missed diagnosis.
- name: S-sulfocysteine
  presence: INCREASED
  context: >
    Elevated plasma and/or urinary S-sulfocysteine is the most consistent biochemical
    abnormality in ISOD, reported in every published case, and is simultaneously the
    proximate neurotoxin.
  biomarker_term:
    preferred_term: S-sulfo-L-cysteine
    term:
      id: CHEBI:62225
      label: S-sulfo-L-cysteinate(1-)
  evidence:
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasma or urinary S-sulfocysteine levels were elevated in all cases."
    explanation: Establishes S-sulfocysteine elevation as present in 100% of published cases.
- name: Urinary thiosulfate
  presence: INCREASED
  context: >
    Thiosulfate is the second sulfite disposal product and is elevated in urine. In
    the SUOX-knockout mouse it accumulates 45-fold and is the major excreted sulfur
    metabolite.
  biomarker_term:
    preferred_term: thiosulfate
    term:
      id: CHEBI:26977
      label: thiosulfate
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
    explanation: Documents elevated urinary thiosulfate in patients.
  - reference: PMID:41178722
    reference_title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Among the urinary biomarkers, thiosulfate showed a 45-fold accumulation in SOXD mice, representing the major excreted S-metabolite."
    explanation: Quantifies thiosulfate as the dominant excreted sulfur metabolite in the knockout mouse.
- name: Plasma total homocysteine
  presence: DECREASED
  context: >
    Markedly reduced — often undetectable — plasma total homocysteine is a
    counterintuitive but highly useful discriminator: most inborn errors on this
    pathway raise homocysteine, whereas ISOD lowers it.
  biomarker_term:
    preferred_term: L-homocysteine
    term:
      id: CHEBI:17588
      label: L-homocysteine
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
    explanation: Documents markedly reduced plasma total homocysteine as a diagnostic clue.
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasma total homocysteine was not detectable."
    explanation: Case-level confirmation that plasma total homocysteine can be undetectable.
- name: Plasma cystine
  presence: DECREASED
  context: >
    Plasma cystine falls because it is consumed in the non-enzymatic reaction with
    sulfite that generates S-sulfocysteine.
  biomarker_term:
    preferred_term: L-cystine
    term:
      id: CHEBI:16283
      label: L-cystine
  evidence:
  - reference: PMID:9050047
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was increased urine excretion of sulfite and S-sulfocysteine and a decreased concentration of plasma cystine."
    explanation: Documents low plasma cystine alongside the sulfite/S-sulfocysteine elevation.
- name: Plasma uric acid and urinary oxypurines
  presence: NORMAL
  context: >
    Normal uric acid and urinary oxypurines are what make the deficiency "isolated":
    they exclude molybdenum cofactor deficiency, in which xanthine dehydrogenase is
    also lost. This is the single most important discriminating test because MoCD
    type A is treatable and ISOD is not.
  biomarker_term:
    preferred_term: uric acid
    term:
      id: CHEBI:27226
      label: uric acid
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of uric acid (plasma) and oxypurines (urine) is useful to rule out MoCD."
    explanation: Establishes uric acid and urinary oxypurines as the tests that distinguish ISOD from MoCD.
genetic:
- name: SUOX deficiency
  gene_term:
    preferred_term: SUOX
    term:
      id: hgnc:11460
      label: SUOX
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
    description: Biallelic pathogenic SUOX variants are required; heterozygous carriers are asymptomatic.
    evidence:
    - reference: PMID:28933809
      reference_title: "Isolated Sulfite Oxidase Deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ISOD is inherited in an autosomal recessive manner."
      explanation: States the autosomal recessive mode of inheritance.
  features: >
    SUOX encodes sulfite oxidase, a homodimeric molybdenum-cofactor- and
    heme-containing enzyme; the carboxy-terminal third of the protein carries most of
    the contacts required for dimerization, so truncating variants in that region
    abolish activity. Reported alleles span truncating and missense classes: a
    homozygous 4-bp deletion (c.1347_1350delTTGT) segregates as a founder allele in
    an Indigenous genetic isolate in Manitoba, Canada, and missense alleles have been
    described in the milder, ectopia-lentis-predominant presentation. A published
    systematic review realigned all reported SUOX variants to the reference sequence
    NM_000456.2.
  evidence:
  - reference: PMID:33335014
    reference_title: "Isolated sulfite oxidase deficiency: a founder mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both patients have a homozygous 4-bp deletion, 1347-1350delTTGT in the sulfite oxidase gene (SUOX), predicting a premature termination of the sulfite oxidase protein leading to absence of the carboxy-terminal third portion of the protein."
    explanation: Describes the Manitoba founder truncating allele and its predicted protein consequence.
  - reference: PMID:33335014
    reference_title: "Isolated sulfite oxidase deficiency: a founder mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This domain contains most of the contact sites essential for enzyme dimerization."
    explanation: Explains why loss of the carboxy-terminal third abolishes enzyme function.
  - reference: PMID:9050047
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A point mutation that resulted in a truncated protein missing the molybdenum-binding site has been identified."
    explanation: Documents an early truncating allele removing the molybdenum-binding site.
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also aligned the published SUOX gene mutations to the reference sequence NM_000456.2."
    explanation: Records the systematic realignment of published SUOX variants to a single reference transcript.
  - reference: PMID:36303223
    reference_title: "Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genotype-phenotype analysis demonstrated patients with biallelic missense mutations had milder symptoms"
    explanation: >-
      Establishes a genotype-phenotype correlation in which biallelic missense
      genotypes produce a milder course than truncating genotypes.
treatments:
- name: Anticonvulsant therapy for seizures
  description: >
    Anti-seizure medication is the mainstay of symptomatic management, although the
    neonatal seizures of classic ISOD are characteristically pharmacoresistant —
    consistent with the mechanism, in which glutamatergic drive is increased and
    GABAergic inhibitory synapses are actively degraded.
  treatment_term:
    preferred_term: anticonvulsant agent therapy
    term:
      id: NCIT:C64172
      label: Anticonvulsant Therapy
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
  notes: >-
    Deliberately carries no `target_mechanisms` edge. Most anti-seizure medications
    act by potentiating GABAergic inhibitory transmission, but in ISOD those
    inhibitory synapses are themselves being destroyed by calpain-dependent gephyrin
    degradation ("Loss of GABAergic Inhibition") — the drug class is aimed at a node
    whose substrate is disappearing, which is the mechanistic account of the
    characteristic pharmacoresistance. Asserting a therapeutic edge here would
    overstate an effect the literature reports as absent.
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptomatic treatment can include: anti-seizure medication (ASM) for seizures; medications to reduce spasticity; and early consideration of gastrostomy tube placement to manage difficulties with swallowing, assure adequate caloric intake, and reduce risk of aspiration."
    explanation: Documents anti-seizure medication as recommended symptomatic management.
- name: Gastrostomy tube placement
  description: >
    Early gastrostomy is recommended to manage swallowing difficulty, secure caloric
    intake and reduce aspiration risk.
  treatment_term:
    preferred_term: gastrostomy
    term:
      id: NCIT:C52006
      label: Gastrostomy
  therapeutic_modality: SURGERY
  target_phenotypes:
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptomatic treatment can include: anti-seizure medication (ASM) for seizures; medications to reduce spasticity; and early consideration of gastrostomy tube placement to manage difficulties with swallowing, assure adequate caloric intake, and reduce risk of aspiration."
    explanation: Documents early gastrostomy as recommended management of feeding difficulty.
- name: Methionine- and cysteine-restricted diet
  description: >
    Dietary restriction of the sulfur amino acids methionine and cysteine aims to
    reduce the substrate load entering the blocked pathway. Reported benefit is
    limited and confined to late-presenting, milder patients: in a literature review
    of all published cases, clinical improvement on dietary therapy was seen in only
    two patients, both presenting after six months of age with relatively mild
    developmental delay. It is not effective in classic neonatal-onset disease.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  therapeutic_modality: BEHAVIORAL
  target_mechanisms:
  - target: Sulfite Accumulation
    treatment_effect: INHIBITS
    description: >-
      Restricting dietary methionine and cysteine lowers the flux of sulfur amino
      acids entering catabolism upstream of the blocked step, reducing the rate at
      which sulfite is generated. The effect is inherently partial because cysteine
      is also supplied endogenously by protein turnover, which is the mechanistic
      reason dietary therapy helps only the mildest, later-presenting patients.
  evidence:
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical improvement with dietary therapy was seen in only 2 patients, both of whom presented after the age of 6 months and had relatively mild developmental delays."
    explanation: >-
      Supports a limited benefit of dietary therapy restricted to milder,
      later-presenting patients; classified PARTIAL because benefit was seen in only
      2 of the reviewed cases.
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient began a low-methionine and low-cysteine diet and was treated with thiamine and dextromethorphan."
    explanation: Documents the composition of the dietary intervention used in ISOD.
- name: Dextromethorphan
  description: >
    Dextromethorphan is a non-competitive NMDA-receptor antagonist and is the
    clinical counterpart of the central excitotoxic mechanism: if S-sulfocysteine
    injures neurons by agonising the NMDA receptor, blocking that receptor should be
    protective. It has been given to ISOD patients alongside diet and thiamine, and a
    glutamatergic-receptor antagonist alleviates the SSC-induced seizure phenotype in
    zebrafish. No controlled human efficacy data exist, and the HUMAN_MODEL_MISMATCH
    discussion records a dissenting in-vitro report in which glutamate-receptor
    blockade failed to rescue SSC toxicity — so this is curated as a
    mechanism-motivated, unproven intervention rather than an effective therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dextromethorphan
      term:
        id: CHEBI:4470
        label: dextromethorphan
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: NMDA Receptor Overactivation and Calcium Influx
    treatment_effect: INHIBITS
    description: >-
      NMDA-receptor antagonism is intended to block the proximal excitotoxic step —
      SSC-driven receptor overactivation and the calcium influx it gates — upstream
      of calpain activation and neuronal death.
  evidence:
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient began a low-methionine and low-cysteine diet and was treated with thiamine and dextromethorphan."
    explanation: >-
      Documents clinical use of dextromethorphan in ISOD. Classified PARTIAL because
      the report establishes that the drug was administered but not that it altered
      the disease course.
  - reference: PMID:31001109
    reference_title: "S-Sulfocysteine Induces Seizure-Like Behaviors in Zebrafish."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Seizure-like movements were fully revertible upon removal of SSC or could be alleviated by a glutamatergic receptor antagonist."
    explanation: >-
      Provides the in vivo rationale — glutamatergic-receptor antagonism alleviates
      the SSC-induced seizure phenotype in zebrafish larvae.
  - reference: PMID:39749013
    reference_title: "S-Sulfocysteine's toxic effects on HT-22 cells are not triggered by glutamate receptors, nor do they involve apoptotic or genotoxicity mechanisms."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "The cytotoxic effects of SSC were not reversed by glutamate receptor blocker administration."
    explanation: >-
      Directly challenges the rationale for receptor antagonism by showing a
      receptor-independent route to SSC cytotoxicity in HT-22 hippocampal cells.
      Retained so the therapeutic hypothesis is not presented as settled.
- name: Sulfite scavenging (investigational)
  description: >
    The first mechanism-based therapeutic concept for ISOD. Because the disease is
    driven by what accumulates rather than by what fails to be made, chemically
    removing sulfite should be disease-modifying regardless of the enzyme defect.
    Oxidized glutathione and glutathione trisulfide scavenge sulfite in vitro and in
    vivo and extend the lifespan of SOX-knockout mice. This is preclinical only — no
    human data exist — and is curated to record the mechanistic target, not an
    available therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: glutathione disulfide (oxidized glutathione)
      term:
        id: CHEBI:17858
        label: glutathione disulfide
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Sulfite Accumulation
    treatment_effect: INHIBITS
    description: >-
      Scavengers react with sulfite directly, lowering its tissue concentration and
      therefore the formation of both downstream toxic products — S-sulfocysteine
      (the excitotoxic arm) and sulfite-driven persulfide stripping (the H2S arm).
      This is the one node at which a single intervention addresses both arms of the
      pathograph.
  evidence:
  - reference: PMID:41178722
    reference_title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "oxidized glutathione and glutathione trisulfide were able to scavenge sulfite in vitro and in vivo, extending the lifespan of SOXD mice and providing a mechanistic concept of sulfite scavenging for the treatment of this severe metabolic disorder of cysteine catabolism."
    explanation: >-
      Demonstrates sulfite scavenging and a survival benefit in the SOX-knockout
      mouse, establishing the mechanistic concept. Model-organism evidence only — no
      human efficacy is claimed.
- name: Spasticity management
  description: >
    Medications to reduce spasticity are part of the recommended symptomatic regimen
    for the spastic quadriplegia and abnormal tone of classic ISOD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptomatic treatment can include: anti-seizure medication (ASM) for seizures; medications to reduce spasticity; and early consideration of gastrostomy tube placement to manage difficulties with swallowing, assure adequate caloric intake, and reduce risk of aspiration."
    explanation: GeneReviews lists spasticity-reducing medication among recommended symptomatic measures.
- name: Chest physiotherapy
  description: >
    Vigorous chest physiotherapy is recommended to prevent the respiratory
    complications that follow from bulbar dysfunction and aspiration risk.
  treatment_term:
    preferred_term: chest physiotherapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other measures can include vigorous chest physiotherapy to prevent respiratory complications."
    explanation: GeneReviews recommends vigorous chest physiotherapy for respiratory prophylaxis.
- name: Supportive and multidisciplinary care
  description: >
    No treatment exists for the underlying metabolic defect, so care is supportive:
    spasticity management, nutrition, respiratory care and periodic multidisciplinary
    surveillance of neurologic and nutritional status.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No treatment exists for the underlying metabolic defect."
    explanation: Establishes that management is symptomatic/supportive only.
- name: Genetic counseling
  description: >
    Autosomal recessive counseling with a 25% sibling recurrence risk; once the
    biallelic SUOX variants are known, carrier testing, prenatal testing and
    preimplantation genetic testing are available.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: Provides the recurrence risks that underpin genetic counseling.
diagnosis:
- name: Urinary sulfite dipstick screening
  description: >-
    A bedside dipstick positive for urinary sulfite is the fastest pointer to ISOD in
    a neonate with intractable seizures. It is a screening test only: sulfite is
    unstable and oxidises on standing, so a fresh sample is required and a negative
    result does not exclude the diagnosis. A positive dipstick does not distinguish
    ISOD from molybdenum cofactor deficiency, which produces the same secondary
    sulfite oxidase block.
  diagnosis_term:
    preferred_term: laboratory test
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: >-
    Dipstick positive for urinary sulfite in a fresh specimen supports ISOD or
    molybdenum cofactor deficiency.
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
    explanation: GeneReviews lists a positive urinary sulfite dipstick among the laboratory findings that suggest ISOD.
- name: Sulfur metabolite panel (thiosulfate, S-sulfocysteine, organic sulfate, total homocysteine)
  description: >-
    The biochemical signature of ISOD is a paired pattern: the sulfite disposal
    products rise while the oxidative end product and the transsulfuration pool fall.
    Elevated urinary thiosulfate and S-sulfocysteine with LOW urinary organic sulfate
    and markedly LOW plasma total homocysteine is close to specific. The low total
    homocysteine is the discriminating feature against the neighbouring sulfur amino
    acid disorders (CBS-deficient homocystinuria raises it), and is easy to misread as
    a normal or reassuring result.
  diagnosis_term:
    preferred_term: laboratory test
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: >-
    Elevated urinary thiosulfate and S-sulfocysteine with low urinary organic sulfate
    and markedly reduced plasma total homocysteine.
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory findings that suggest the diagnosis of ISOD are dipstick positive for urinary sulfite, elevated urinary thiosulfate and S-sulfocysteine, low urinary organic sulfate, and markedly reduced plasma levels of total homocysteine."
    explanation: Specifies the full suggestive metabolite panel, including the counterintuitive low organic sulfate and low total homocysteine.
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasma or urinary S-sulfocysteine levels were elevated in all cases."
    explanation: Establishes S-sulfocysteine elevation as an invariant finding across published cases, supporting its diagnostic sensitivity.
- name: Discrimination from molybdenum cofactor deficiency
  description: >-
    Because MoCD produces an identical secondary sulfite oxidase block, the metabolite
    panel alone cannot separate the two. The distinguishing test exploits the fact
    that ISOD spares the other molybdenum-cofactor-dependent enzymes: xanthine
    dehydrogenase activity and purine handling are normal in ISOD, so plasma uric acid
    and urinary xanthine/hypoxanthine are normal, whereas MoCD gives low uric acid
    with elevated xanthine. This distinction changes management, since MoCD type A is
    treatable with fosdenopterin and ISOD is not.
  diagnosis_term:
    preferred_term: laboratory test
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: >-
    Normal uric acid and normal urinary oxypurines indicate isolated sulfite oxidase
    deficiency rather than molybdenum cofactor deficiency.
  evidence:
  - reference: PMID:9050047
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver sulfite oxidase activity was not detectable but xanthine dehydrogenase activity was normal."
    explanation: >-
      Demonstrates the enzymatic pattern that defines the isolated form — absent
      sulfite oxidase with preserved xanthine dehydrogenase, i.e. an intact
      molybdenum cofactor.
- name: SUOX molecular genetic testing
  description: >-
    Identification of biallelic pathogenic SUOX variants is the confirmatory test and
    the basis for subsequent carrier, prenatal and preimplantation genetic testing.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: Biallelic pathogenic SUOX variants confirm the diagnosis.
  evidence:
  - reference: PMID:28933809
    reference_title: "Isolated Sulfite Oxidase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis is confirmed by identification of biallelic pathogenic variants in SUOX by molecular genetic testing."
    explanation: GeneReviews states that molecular genetic testing provides diagnostic confirmation.
  - reference: PMID:36303223
    reference_title: "Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Isolated sulfite oxidase deficiency (ISOD) caused by sulfite oxidase gene (SUOX) mutations is a rare neurometabolic disease associated with ectopia lentis (EL)."
    explanation: >-
      Supports SUOX sequencing as the route to diagnosis in patients ascertained
      through ectopia lentis rather than neonatal encephalopathy — the late-onset
      presentation most likely to be missed.
- name: Brain MRI
  description: >-
    Neuroimaging is abnormal in every ISOD patient imaged in the largest published
    review, typically showing diffuse cerebral atrophy, cystic encephalomalacia and
    ventriculomegaly. The pattern strongly resembles hypoxic-ischaemic injury, so
    imaging supports but does not establish the diagnosis and is a recognised route to
    misattributing ISOD to perinatal asphyxia.
  diagnosis_term:
    preferred_term: magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  results: >-
    Cerebral atrophy with cystic encephalomalacia and ventriculomegaly; mimics
    hypoxic-ischaemic encephalopathy.
  evidence:
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all patients in whom brain magnetic resonance imaging/computed tomography (MRI/CT) was performed, brain abnormalities were found."
    explanation: Establishes that structural brain abnormality is an invariant imaging finding in ISOD.
differential_diagnoses:
- name: Molybdenum cofactor deficiency
  description: >
    MoCD produces an identical secondary sulfite oxidase deficiency plus loss of
    xanthine dehydrogenase and aldehyde oxidase, and is clinically very similar at
    the bedside. The distinction is critical because MoCD type A is treatable whereas
    ISOD is not.
  distinguishing_features:
  - >-
    Plasma uric acid and urinary oxypurines are normal in ISOD but abnormal in MoCD,
    reflecting the additional loss of xanthine dehydrogenase in MoCD.
  - >-
    Direct liver enzyme assay shows absent sulfite oxidase with normal xanthine
    dehydrogenase activity in ISOD.
  evidence:
  - reference: PMID:16140720
    reference_title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main alternative in the differential diagnosis of isolated sulfite oxidase deficiency is molybdenum cofactor deficiency."
    explanation: Identifies MoCD as the principal differential diagnosis.
  - reference: PMID:28980090
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As no long-term effective treatment is available, distinction from other treatable diseases, such as molybdenum cofactor deficiency (MoCD) type A, should be made."
    explanation: States why the distinction matters clinically — MoCD type A is treatable and ISOD is not.
  - reference: PMID:9050047
    reference_title: "Isolated sulfite oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver sulfite oxidase activity was not detectable but xanthine dehydrogenase activity was normal."
    explanation: Documents the enzymatic pattern that distinguishes ISOD from MoCD.
discussions:
- discussion_id: ssc_nmda_evidence_from_mocd
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Does S-sulfocysteine drive NMDA-receptor-dependent excitotoxicity in human
    isolated sulfite oxidase deficiency to the same degree demonstrated in molybdenum
    cofactor deficiency models?
  attaches_to:
  - "pathophysiology#NMDA Receptor Overactivation and Calcium Influx"
  - "pathophysiology#Calpain Activation and Gephyrin Degradation"
  - "pathophysiology#Loss of GABAergic Inhibition"
  rationale: >-
    The mechanistic chain curated here — SSC acting as an NMDA-receptor agonist,
    calcium influx, calpain activation, calpain-dependent gephyrin degradation and
    loss of GABAergic synapses — was demonstrated in primary murine neurons and in a
    tungstate-induced molybdenum cofactor deficiency mouse, not in ISOD patients or
    ISOD-derived human neurons. The transfer is biologically reasonable because MoCD
    causes a secondary sulfite oxidase block and therefore the same accumulating
    metabolite, and because a full SUOX-knockout mouse now exists. But the two
    disorders are not metabolically identical: MoCD additionally loses xanthine
    dehydrogenase and aldehyde oxidase, so MoCD models carry purine and aldehyde
    perturbations that ISOD does not. A dissenting in-vitro report in HT-22
    hippocampal cells further found that glutamate-receptor blockade did NOT reverse
    SSC cytotoxicity, implying at least one receptor-independent death pathway.
    Whether NMDA-receptor antagonism would be neuroprotective in human ISOD is
    therefore genuinely open, and it matters directly because it is the only
    mechanism-based therapeutic hypothesis currently on the table for a disorder with
    no disease-modifying treatment.
  proposed_experiments:
  - experiment_id: isod_nmda_antagonism_suox_ko
    name: NMDA-receptor antagonism in the SUOX-knockout mouse
    description: >-
      Test whether memantine or another NMDA-receptor antagonist is neuroprotective in
      the SUOX-knockout mouse, in which the metabolic lesion is isolated, rather than
      in the tungstate-induced MoCD model where xanthine dehydrogenase and aldehyde
      oxidase are also inhibited.
    decision_criterion: >-
      Significant improvement in survival and in seizure/neurobehavioural endpoints
      versus vehicle would support translating the MoCD mechanism to ISOD; absence of
      benefit would indicate the excitotoxic arm is not rate-limiting in isolated SUOX
      loss.
  - experiment_id: isod_ipsc_neuron_ssc_challenge
    name: ISOD patient iPSC-derived neuron challenge
    description: >-
      Differentiate neurons from ISOD-patient iPSCs and isogenic corrected controls and
      measure SSC-driven calcium influx, calpain activation and gephyrin loss.
    decision_criterion: >-
      Reproduction of the calcium/calpain/gephyrin cascade in human ISOD neurons would
      close the species and disease-context gap in the current evidence.
  - experiment_id: isod_ht22_discrepancy_resolution
    name: Reconciliation of the HT-22 negative result
    description: >-
      Compare SSC cytotoxicity with and without glutamate-receptor blockade across
      primary neurons, HT-22 cells and human iPSC-derived neurons under matched SSC
      concentrations and exposure times.
    decision_criterion: >-
      Consistent receptor-independent toxicity across models would establish a second,
      parallel death pathway (oxytosis/necrosis) that the current pathograph does not
      represent.
  evidence:
  - reference: PMID:29106383
    reference_title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the NMDA-R antagonist memantine was protective against the manifestation of symptoms in a tungstate-induced MoCD mouse model"
    explanation: >-
      The therapeutic proof-of-concept was obtained in a tungstate-induced MoCD mouse,
      not in an ISOD model, which is the source of the translational uncertainty.
  - reference: PMID:39749013
    reference_title: "S-Sulfocysteine's toxic effects on HT-22 cells are not triggered by glutamate receptors, nor do they involve apoptotic or genotoxicity mechanisms."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "The cytotoxic effects of SSC were not reversed by glutamate receptor blocker administration."
    explanation: >-
      A direct in-vitro challenge to the receptor-dependent model: in HT-22
      hippocampal cells, glutamate-receptor blockade did not rescue SSC toxicity,
      indicating at least one receptor-independent death pathway.
- discussion_id: ectopia_lentis_mechanism_unresolved
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    By what mechanism does sulfite accumulation dislocate the ocular lens in ISOD?
  attaches_to:
  - "pathophysiology#Ectopia Lentis"
  rationale: >-
    Ectopia lentis is the one consistent extraneurological feature of ISOD and can be
    the presenting sign of the late-onset form, yet the pathograph has no evidenced
    step connecting sulfite accumulation to zonular failure. The widely repeated
    explanation — that sulfite, a nucleophile, cleaves the disulfide bonds that
    cross-link the fibrillin-rich zonular fibres suspending the lens — is mechanically
    plausible and would explain the phenotypic overlap with homocystinuria and Marfan
    syndrome, but no primary study establishing it in ISOD tissue was identified
    during curation. The node is therefore curated as a consequence carrying a
    clinical association only, and the proposed zonular mechanism is deliberately
    excluded from the evidenced causal chain.
  proposed_experiments:
  - experiment_id: isod_zonule_fibrillin_analysis
    name: Zonular fibre analysis in SUOX-deficient tissue
    description: >-
      Histological and biochemical analysis of zonular fibres from SUOX-knockout mice
      or from ISOD autopsy/lensectomy material, assaying fibrillin-1 disulfide
      integrity against age-matched controls.
    decision_criterion: >-
      Demonstration of reduced disulfide cross-linking or fragmented fibrillin
      microfibrils in SUOX-deficient zonules would convert the hypothesis into an
      evidenced pathograph step.
  - experiment_id: isod_sulfite_microfibril_challenge
    name: In-vitro sulfite challenge of fibrillin microfibrils
    description: >-
      Expose purified fibrillin microfibrils to pathophysiological sulfite
      concentrations and measure disulfide reduction and mechanical failure.
    decision_criterion: >-
      Concentration-dependent disulfide reduction and loss of tensile integrity at
      patient-range sulfite levels would establish chemical plausibility.
  - experiment_id: isod_genotype_lens_onset_correlation
    name: Genotype-stratified age at lens dislocation
    description: >-
      Correlate age at lens subluxation with residual SUOX activity (or genotype
      class) across the published patient spectrum.
    decision_criterion: >-
      A dose-dependent relationship between residual enzyme activity and later
      dislocation would support a cumulative sulfite-exposure mechanism.
notes: >
  ISOD is best understood as a "toxic-metabolite excitotoxicity" disorder rather than
  a classical deficiency state: the harm comes from what accumulates (sulfite and
  especially S-sulfocysteine), not from what fails to be made (sulfate). That framing
  explains several otherwise odd features of the entry. First, plasma total
  homocysteine and cystine are LOW rather than high, which is diagnostically valuable
  precisely because it is the opposite of the pattern in the neighbouring sulfur
  amino acid disorders such as CBS-deficient homocystinuria. Second, the seizures are
  pharmacoresistant not by accident but by mechanism — S-sulfocysteine increases
  glutamatergic drive while calpain simultaneously degrades gephyrin and dismantles
  the inhibitory synapses that many anti-seizure drugs act through — which is why the
  "Loss of GABAergic Inhibition" node conforms to
  `epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance` while
  being reached through a chain that also raises excitation, i.e. the balance is
  shifted from both directions at once. Third, the near-total absence of therapy follows from the
  block being terminal and irreversible: there is no cofactor to replace (unlike MoCD
  type A) and dietary substrate restriction only marginally slows a pathway that is
  also fed endogenously.

  Two curation caveats should be read alongside the pathograph. (i) The
  excitotoxicity mechanism is evidenced chiefly from molybdenum cofactor deficiency
  models and primary murine neurons rather than from ISOD patients, and one in-vitro
  study directly contradicts the receptor-dependent account — see the
  HUMAN_MODEL_MISMATCH discussion, which carries that REFUTE evidence. (ii) The
  persulfidation/H2S arm (Fu et al. 2025) comes entirely from the new SUOX-knockout
  mouse; it is mechanistically important because it connects ISOD to the hydrogen
  sulfide disorders such as ETHE1 deficiency and supplies the rationale for sulfite
  scavenging with oxidized glutathione, but it has not yet been demonstrated in
  patients.

  Death in infancy is modeled as a pathophysiology consequence node rather than as a
  `phenotypes` entry because HP:0001522 (Death in infancy) sits outside the
  Phenotypic abnormality subtree that the `PhenotypeTerm` dynamic enum draws from.

  Ectopia lentis is reached from Sulfite Accumulation by a deliberately weak edge —
  `INDIRECT_UNKNOWN_INTERMEDIATES`, opted into the `zonular_disulfide_reduction`
  hypothesis group, and evidenced only by the clinical co-occurrence (`PARTIAL`).
  This keeps the pathograph a single connected component without asserting the
  unsourced zonular-disulfide mechanism as fact; the gap itself is recorded in the
  `ectopia_lentis_mechanism_unresolved` KNOWLEDGE_GAP discussion.

  Two frequency bands were deliberately omitted. Axial hypotonia and Neonatal seizure
  both draw on PMID:28980090, but the 100% figure there covers the disjunction "axial
  hypotonia and/or peripheral hypertonia" and the 84% figure counts seizures at any
  age (neonatal onset was 57%). Neither number quantifies the specific term used
  here, so per `docs/frequency-evidence-guidelines.md` no band is asserted. Global
  developmental delay keeps `VERY_FREQUENT` because its 97% is a clean single figure
  for that phenotype.

  Anti-seizure medication carries no `target_mechanisms` edge on purpose. Most such
  drugs act by potentiating GABAergic transmission, and in ISOD those synapses are
  the ones being destroyed — the absence of a therapeutic edge is the mechanistic
  statement, and asserting one would overstate an effect the literature reports as
  absent.

  Relationship to other dismech entries: ETHE1-deficiency `Ethylmalonic
  Encephalopathy` is the closest mechanistic neighbour (both are disorders of
  sulfur-containing amino acid and hydrogen sulfide metabolism, curated in the same
  IEMbase package WP-002), and molybdenum cofactor deficiency is the principal
  differential diagnosis but is a distinct, not-yet-curated entity because its lesion
  is in cofactor biosynthesis rather than in SUOX itself.
references:
- reference: PMID:28933809
  title: "Isolated Sulfite Oxidase Deficiency."
  tags:
  - GeneReviews
- reference: PMID:28980090
  title: "Isolated sulfite oxidase deficiency."
- reference: PMID:29106383
  title: "S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency."
- reference: PMID:41178722
  title: "Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release."
- reference: PMID:33335014
  title: "Isolated sulfite oxidase deficiency: a founder mutation."
- reference: PMID:36303223
  title: "Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation."
- reference: PMID:16140720
  title: "Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature."
- reference: PMID:9050047
  title: "Isolated sulfite oxidase deficiency."
- reference: PMID:31001109
  title: "S-Sulfocysteine Induces Seizure-Like Behaviors in Zebrafish."
- reference: PMID:39749013
  title: "S-Sulfocysteine's toxic effects on HT-22 cells are not triggered by glutamate receptors, nor do they involve apoptotic or genotoxicity mechanisms."
📚

References & Deep Research

References

10
PMID:28933809
Isolated Sulfite Oxidase Deficiency.
No top-level findings curated for this source.
PMID:28980090
Isolated sulfite oxidase deficiency.
No top-level findings curated for this source.
PMID:29106383
S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency.
No top-level findings curated for this source.
PMID:41178722
Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release.
No top-level findings curated for this source.
PMID:33335014
Isolated sulfite oxidase deficiency: a founder mutation.
No top-level findings curated for this source.
PMID:36303223
Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation.
No top-level findings curated for this source.
PMID:16140720
Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature.
No top-level findings curated for this source.
PMID:9050047
Isolated sulfite oxidase deficiency.
No top-level findings curated for this source.
PMID:31001109
S-Sulfocysteine Induces Seizure-Like Behaviors in Zebrafish.
No top-level findings curated for this source.
PMID:39749013
S-Sulfocysteine's toxic effects on HT-22 cells are not triggered by glutamate receptors, nor do they involve apoptotic or genotoxicity mechanisms.
No top-level findings curated for this source.